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ABSTRACT 
Cutaneous Malignant Melanoma is a highly aggressive form of skin cancer that 
has a tendency to metastasise. In its early stages, the 5-year survival rate of 
patients is greater than 90% following surgical excision of an in situ tumour. 
However, following metastasis of the tumour, the 5-year survival rate declines to 
5-35%. Due to the correlation between metastasis and declining survival, 
studies have attempted to identify potential metastasis as early as possible. 
Molecular markers of melanoma cells in the peripheral blood of CMM patients 
have been investigated, as the invasion of tumour cells into the blood is one of 
the first events in melanoma metastasis. Genetic markers PAX3d, MITF, 
MART1, SFRP5 andTGF{32 are involved in the development, proliferation and 
migration of melanocytic cells, and are aberrantly expressed in melanoma. 
Therefore, the aim of this study was to develop an assay that can be used for 
CMM diagnosis and prognosis and to assess PAX3d, MITF, SFRP5, MART1 
and TGF-{32 expression in peripheral blood of CMM patients relative to healthy 
volunteers. 
In this study, lymph node tissue and peripheral blood samples were taken from 
CMM patients and blood was donated from healthy volunteers. Total RNA was 
extracted from all samples and following the analysis of RNA quality, samples 
were Reverse Transcribed. The resu!ting eDNA was analysed by PCR for the 
expression of the housekeeping gene GAPDH, following which samples 
expressing this gene were analysed by PCR for the presence of each of the 
genetic markers: PAX3d, MITF, MART1, SFRP5 and TGF{32. 
Statistical analysis of marker expression showed that CMM patients were 
significantly more likely than healthy volunteers to express one or more 
markers, as well as significantly higher expression of MITF, TGF{32 and MART1 
in patients relative to healthy volunteers. The number of markers shown in each 
sample was statistically analysed and showed that a significantly higher 
frequency of TGF{32 expression correlated with primary tumours of >2.00mm in 
CMM patients, as well as a significantly lower frequency of MART1 expression 
in patients with a tumour depth of 0.01-2.00mm relative to patients with in situ 
iv 
melanoma or >2.00mm tumour depth. Frequent expression of all markers in 
CMM patients even after more than one year since diagnosis suggests the 
longevity of melanoma cells in the blood. The results presented here show that 
MITF, MART1 and TGF{32 are sensitive and useful markers of melanoma cells 
in the peripheral blood of CMM patients even after more than one year since 
diagnosis. 
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1. INTRODUCTION 
1.1. Cutaneous Malignant Melanoma 
Cutaneous Malignant Melanoma (CMM) is a form of skin cancer that arises 
from cutaneous melanocytic cells. Although a rare form of skin cancer, it is 
responsible for almost 80% of skin cancer related deaths due to a strong 
metastatic tendency (Lewis eta/., 2005). 
The American Joint Committee on Cancer (AJCC) has provided a classification 
system for the stages of melanoma development based on tumour thickness 
and ulceration as well as lymphatic and systemic metastasis (Balch et a/., 
2001 ). According to this classification system, prognosis of a patient is closely 
related to metastasis of CMM; patients undergoing the surgical excision of a 
thin, non-metastatic melanoma have a greater than 90% five-year survival rate, 
while patients with metastasis of a thicker tumour have a far poorer prognosis 
and a 5-35% five-year survival rate (Balch eta/., 2001; Wascher eta/., 2003). 
Metastasis is commonly detected in sentinel lymph nodes as a result of an 
invasive biopsy or a Positron Emission Tomography (PET) scan (Holder eta/., 
1998). Recent studies have attempted to use circulating melanoma cells in the 
blood stream as an indicator of spreaq of the disease. Invasion of tumour cells 
into the blood is one of the first events in melanoma metastasis and screening 
the blood for melanoma markers allows early identification of potential 
metastasis (Wascher et a/., 2003). A blood test for CMM would also act as an 
important prognostic tool as earlier detection of metastatic spread may suggest 
that a more appropriate treatmenf relative to disease progression is required. 
1.2. Molecular Markers for CMM haematological spread 
There are many potentially suitable molecular markers currently being assessed 
in several research labs. This research involves screening of CMM patient 
blood for melanoma markers. These markers range from genes involved in 
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melanocyte production, such as Paired-Box transcription factor (PAX3) and 
Microphthalmia-Associat(;}d Transcription Factor (MITF), to melanin protein 
genes such as tyrosinase, and to genes encoding melanoma-associated 
antigens like Melanoma Antigen Recognised by T-cells (MART1 ). Other genes, 
such as those thought to be. involved in the proliferation of melanoma cells and 
disease progression like Transforming Growth Factor Beta (TGF-{3) and 
Secreted Frizzled-Related Protein 5 (SFRP5) have not been assessed as yet. 
Markers involved in these various pathways have been trialled in this study and 
their presence in peripheral blood of CMM patients has been compared with 
presence in blood from healthy volunteers. 
One potential marker, PAX3, encodes a Paired-Box transcription factor, and is 
expressed early in embryonic development to direct melanogenesis. PAX3-c 
and -d alternative isoforms are known to be aberrantly expressed in melanomas 
and their expression is thought to be restricted to more malignant metastatic 
cells (Vachtenheim and Novotna, 1999). Due to the presence of PAX3 in 
metastatic cells, this transcription factor may be an important marker of 
melanoma cells circulating in blood. 
MITF regulates genes encoding the pigment producing enzymes Tyrosinase 
(TYR), Tyrosinase Related Protein 1 (TYRP1) and Dopachrome Tautomerase 
(OCT) as well as genes responsible for cell proliferation and survival (Wagner 
and Fisher, 2005). Expression of the MITF gene is associated with melanoma 
progression and can therefore be used as a marker of melanoma cell migration 
in the blood (Carreira eta/., 2005). 
MART1 is a melanoma-associated antigen involved in melanosome biogenesis. 
It is a specific marker used in biopsies to differentiate melanoma cells from 
those of other skin malignancies (Wascher eta/., 2003). MART1 has been used 
in this study to mark migrating melanoma cells in peripheral blood as it is the 
most commonly used marker of melanoma. 
SFRPs are upstream regulators of the signaling pathway that controls MITF 
production. SFRP gene expression would therefore be expected to be a marker 
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of early undifferentiated melanoma cells. To date, this marker has not been 
used to detect melanoma cell migration, although low levels of expression of the 
genes have been associated with other forms of cancer (Jones and Jomary, 
2002). In this project SFRP-5 expression was trialed as a marker of migrating 
melanoma cells in peripheral blood. 
TGF-(3 is a multifunctional cytokine involved in many pathways that regulate cell 
function. By activating many different transcription factors, TGF-(3 controls cell 
proliferation, differentiation, apoptosis and neogenesis (Reed et a/., 1994). 
Thus, it is expected that alteration in the level of expression of the gene may 
allow abnormal growth and proliferation of melanoma cells. For these reasons, 
TGF-{3 gene expression was trialled as one of the markers of melanoma cell 
migration in the bloodstream of patients with CMM. 
1.3. Significance of the Study 
With the incidence of CMM rising yearly and relatively little progress being 
made in the treat~ent of this terminal disease, the development of a test for 
screening CMM patients, so as to identify the spread of melanoma cells, is 
rapidly becoming a necessity (Lewis et a/., 2005). As the morbidity of most 
CMM patients is not due to the prim~ry tumour, but to metastatic disease, it is 
important to identify the likelihood of metastasis as early as possible. 
Recent studies have identified gene expression in melanoma cells as useful for 
identification of primary and secondary tumours removed from melanoma 
patients, as well as in the detection of migrating melanoma cells in peripheral 
blood (Palmieri eta/., 1999; Wascher eta/., 2003). Moreover, several studies 
have recognised the necessity of using multiple markers in RT-PCR assays in 
order to improve assay sensitivity (Hoon et a/., 2000; Koyanagi et a/., 2005). 
The particular suite of markers that would give optimal correlation to disease 
stage and progression remains to be clarified. 
4 
In this project, the presence of mRNA transcripts indicative of gene expression 
of Paired-Box Transcription Factor (PAX3), Microphthalmia-Associated 
Transcription Factor (MITF), Secreted Frizzled-Related Proteins (SFRPs), 
Melanoma Antigen Recognised by T-ee/Is (MART1) and Transforming Growth 
Factor Beta (TGF-{3) have been tested in blood and tumour samples from 
patients diagnosed with differing tumour depths, as well as in the peripheral 
blood of healthy volunteers. Results from this study have allowed us to 
determine which of these markers should be included or excluded in an optional 
suite of markers for the detection of migrating melanoma cells. Results have 
been compared with those obtained from previous studies. 
The detection of malignant melanoma cells in patient sera has a diversity of 
applications including disease detection, disease staging, assessing the 
probability of disease recurrence and analysis of treatment efficacy. Accurate 
staging of a patient may be possible by comparing the number and suite of 
markers present in the patient blood relative to a set of markers known to be 
associated with melanoma tissue samples. Such a test would assist in providing 
appropriate adjuvant treatment (Hoon eta/., 2000; Palmieri eta/., 1999). All of 
these applications of marker detection in peripheral blood samples would aid in 
the early diagnosis and staging of CMM, and would assist with disease 
management and treatment possibly leading to improved five-year survival 
rates of patients with the more advanc,ed stages of disease. 
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2. REVIEW OF THE LITERATURE 
2.1. Melanocytes 
Melanocytes are specialised pigment producing cells found in the epidermal 
and dermal layers of the skin (Dupin and LeDouarin, 2003). These cells 
differentiate from melanoblasts which originate from neural crest cells and 
subsequently migrate to the skin during early embryonic development (Blake 
and Ziman, 2005). 
Melanocytes synthesise melanin pigment by the activities of melanin-secreting 
proteins; tyrosinase (TYR), tyrosinase related protein (TYRP1) and dopachrome 
tautomerase (OCT) in response to transcriptional signaling within the cell 
(Hearing, 2000; Wagner and Fisher, 2005). The purpose of melanin pigment is 
to provide photoprotection and thermoregulation of the melanocyte and 
surrounding keratinocytes. These two cell types have a symbiotic relationship in 
which keratinocytes control melanocyte growth, and melanocytes produce 
melanin to protect mitotic keratinocytes from the ionising effect of UV irradiation 
(Haass eta/., 2005). 
2.2. Melanocyte development 
The development of melanocytes from their neural crest origin is closely 
regulated by several transcription factors. These factors affect the migration, 
specification and proliferation of melanoblasts as they migrate to the skin, as 
well as their terminal differentiation into melanocytes once they arrive there 
(Blake and Ziman, 2005). A very complex and intricate network of overlapping 
signaling pathways regulate these processes. 
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2.2.1. MITF expression in melanocyte development 
The microphthalmia-associated transcription factor (MITF) acts as a master 
regulator of melanocyte development, having direct involvement in the 
differentiation, proliferation and survival of these cells (Wagner and Fisher, 
2005). 
The MITF gene has a multi-promoter organization which allows alternative 
splicing to produce several MITF isoforms (Hershey and Fisher, 2005), with the 
M promoter selectively expressed in melanocytes (Fuse eta/., 1996; Udono et 
a/., 2000). MITF-M binds to an M-box sequence (CATGTG or AGTCATGTG) 
found in the promoter regions of MITF responsive genes such as those involved 
in melanogenesis (TYR, TYRP1 and OCT) and apoptosis (BCL2) and is known 
to regulate the expression of these genes (Figure 2.1 b) (Wagner and Fisher, 
2005). 
2.2.2. MITF signaling pathways 
Expression of the MITF-M gene is regulated by an array of transcription factors 
that bind to its promoter (Figure 2.1 a). These include the paired box 
transcription factor (PAX3), sex det~rmining region Y-box 10 (SOX1 0), the 
lymphoid enhancer factor (LEF1) and the cAMP responsive element binding 
transcription factor (CREB) (Vance and Goding, 2004). 
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Figure 2.1. Regulation of Mitt expression and activity. (a) The Mitt-M promoter showing the binding sites 
for transcription factors known to regulate Mitt expression and the signal transduction pathways regulating 
their activity. (b) Features of the Mitf protein. Phosphorylation sites and locations of regions interacting with 
co-factors or other transcription factors are indicated above, while those genes known to be regulated by 
Mitf are shown below (adapted from Vance and Goding, 2004). 
2.2.2.1. PAX3 regulation of MITF 
PAX3 can activate MITF expression by binding to recognition sites located 
upstream of the MITF-M transcript initiation site (Bondurand et a/., 2000; 
Watanabe et a/., 1998). PAX3 can bind independently, or in synergy with 
SOX10 to activate MITF expression (Figure 2.2) (Lang eta/., 2005). 
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Sox10 
Mitf ~ Oct 
Pax3 
Figure 2.2. Pax3 binds to Miff promoters either directly or in synergy with Sox1 0 to up-regulate Miff leading 
to up-regulation of MITF responsive gene Dct (Adapted from Lang eta/, 2005). 
2.2.2.2. LEF1 regulation of MITF 
The LEF1 transcription factor interacts with ~-catenin via the WNT signaling 
pathway to regulate MITF expression (Larue et a/., 2003; Saito et a/., 2003). 
The WNT protein binds to Frizzled receptors, inactivating glycogene synthase 
kinase 3~ (GSK-3~). a kinase that inhibits ~-catenin. Thus, by inactivating GSK-
' 3~, WNT signaling allows accumulation of ~-catenin, which translocates into the 
nucleus and binds with LEF1 to co-activate transcription of MITF (Figure 2.3, 
pathway a.) (Wagner and Fisher, 2005). MITF is then able to induce the 
expression of genes involved in pigmentation, proliferation and survival (Figure 
2.3, pathway b.). 
2.2.2.3. CREB regulation of MITF 
The two signaling pathways that lead to the activation of CREB are the 
melanocyte stimulating hormone (MSH) pathway and the endothelin (END) 
pathway (Wagner and Fisher, 2005). MSH binds to the melanocortin receptor 
(MC1 R) on the surface of the cell and leads to the production of cyclic AMP 
(cAMP). Similarly, END binds to the endothelin 3 receptor (ENDRB) and leads 
to production of cAMP. The cyclic AMP then liberates the catalytic subunit of 
protein kinase A {PKA) allowing it to phosphorylate CREB (Steingrimsson eta/., 
2004 ), which is then able to bind to the cAMP responsive element (CRE) DNA 
binding site on the MITF promoter, thus activating MITF (Figure 2.3, pathway 
c.). 
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Figure 2.3. Normal melanocyte signaling pathways. (a) Stimulation of the Wnt signaling pathway leads to 
inactivation of GSK3B, which inhibits ~-catenin. In this manner, Wnt signaling leads to enhanced 
transcription of MITF by allowing ~-catenin to translocate to the nucleus and cooperate with LEF-1 on the 
MITF promoter. (b) In melanocytes, MITF induces expression of genes involved in pigmentation, 
proliferation and survival. (c) Stimulation of the MSH or endothelin receptors leads to production of cAMP 
which in turn activates protein kinase A (PKA). Phosphorylation of CREB by PKA induces DNA-binding 
and enhances transcription of the MITF promoter (Adapted from Wagner and Fisher, 2005). 
2.2.2.4. SFRP association with MITF expression 
Secreted Frizzled-Related Proteins (SFRPs) are secreted glycoproteins, 
positioned upstream of WNT in the WNT cascade (Jones and Jomary, 2002). 
They contain a cysteine-rich domain homologous to the WNT binding site of 
Frizzled receptors (Uren eta/., 2000). 
At high levels, SFRP acts as an antagonist to WNT signaling by preventing 
WNT interaction with Frizzled receptors (He et a/., 2005). Structurally, it 
resembles a Frizzled receptor, allowing competitive binding with WNT .ligands to 
prevent signaling through the Frizzled receptor. This leads to a decrease in the 
intracellular levels of (3-catenin (Wissmann eta/., 2003). As seen previously in 
Figure 2.3, (3-catenin is required for LEF1 binding of the MITF promoter. Thus, 
by blocking WNT/Frizzled interaction, SFRP represses the expression MITF. At 
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low levels however, SFRP can augment WNT/Frizzled interaction, consequently 
up-regulating MITF (Jones and Jomary, 2002). 
2.2.3. PAX genes in melanocyte development 
The Paired Box (Pax) genes are a family of transcription factors with essential 
and distinct roles in embryonic development (Ziman and White, 2006). Within 
this family of genes, Pax3 is associated with melanoblast proliferation and 
differentiation (Hornyak eta/., 2001 ). 
As described above PAX3 activates MITF transcription leading to the production 
of OCT. At the same time, PAX3 competes with MITF for occupancy of the DCT 
enhancer to repress OCT production, unless displaced from the DNA by 13-
catenin (Figure 2.4 ). 
By repressing DCT expression, PAX3 holds the melanoblast in an 
undifferentiated state while MITF accumulates. The cell is primed for rapid 
expression of downstream genes once the PAX3 mediated repression is 
relieved by 13-catenin. Thus PAX3 acts as a molecular switch allowing the 
undifferentiated melanoblast to proliferate and migrate, or to differentiate once it 
reaches the dermis and PAX3 is down.-regulated (Lang eta/., 2005). 
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Figure 2.4. The role of Pax3 in the specification and differentiation of melanocytes. a) Pax3 binds and 
activates expression Mitt during specification of melanoblasts from neural crest cells. b) Pax3 complexes 
with groucho, repressing the differentiation gene Oct, thus maintaining cells in an undifferentiated state. c) 
Wnt signaling activates ~-catenin which displaces Pax3 and groucho, allowing Mitf to bind and activate 
Oct expression, stimulating melanocyte differentiation (Adapted from Ziman and White, 2006). 
The pathways described above are thought to be re-expressed in melanoma 
(Scholl et a/., 2001 ), leading to aberrant expression of genes controlling 
proliferation, migration and cell survival in melanoma cells. 
2.3. Cutaneous Malignant Melanoma 
Cutaneous Malignant Melanoma (CMM) is a type of skin cancer that is thought 
to arise from melanocytes present in the epidermis. While it accounts for only 
4% of skin cancers, it is responsible for almost 80% of skin cancer related 
deaths due to its aggressive tendency to metastasise (Chang eta/. I 1998; Lewis 
eta/. I 2005). 
Australia has the world's highest incidence of melanoma (Maclennan et a/., 
1992). In Western Australia, melanoma is the third most common cancer in men 
and women over 39 years of age and it is the most common cancer diagnosed 
in the 15-39 year-old age group and it is increasing in incidence by 3% per year 
(Threlfall and Thompson, 2002). 
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2.3.1. Formation and metastasis 
The first event in the formation of a melanoma is thought to be the proliferation 
of structurally normal melanocytes leading to a benign nevus. Next the aberrant 
growth develops to form a dysplastic nevus, within a benign nevus or at a new 
site. At this early stage the tumour is classified as in-situ and is thought to be 
inaccessible to blood and lymphatic vessels (Meier et a/., 1998; Pantel et a/., 
1999). 
There are then 2 stages of melanoma growth: radial and vertical. During the 
radial growth phase, cells aquire the ability to proliferate within the epidermis. In 
the vertical growth phase, cells acquire the ability to invade the dermis and form 
an expansive nodule, widening the papillary dermis with extensions into the 
reticular dermis and fat layers (Miller and Mihm Jr, 2006). At this stage tumours 
are classified as invasive. It is at this stage that the initial risk of metastasis 
exists increasing as the tumour invades the deeper layers (Pantel eta/., 1999). 
Following dermal invasion, metastatic cells can infiltrate the blood and lymphatic 
systems and circulate in the body to new sites where they can adhere to the 
walls of a capillary and invade a new tissue to form a micrometastasis (Pantel et 
a/., 1999). Once the CMM reaches the subcutaneous fat tissue, the risk of 
metastasis is high and systemic meta.stases are likely to occur. This process is 
shown diagrammatically in figure 2.5 below. 
For metastases to be formed, metastatic cells must undergo delamination, 
migration through tissues and adhesion at secondary sites, processes which 
they undergo while in a relatively undifferentiated state (Ziman and White, 
2006). 
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Figure 2.5. Diagram of tumour cell metastasis. Cells from the primary tumour leave the tumour as a result 
of proteolysis, infiltrate and invade the circulatory system and migrate to a new site where they adhere to 
the walls of the capillary and invade a new organ. At these sites micrometastases, isolated tumour cells or 
small clusters of tumour cells, undetectable by conventional tumour detection procedures can survive for 
several years. At some later stage, the cells become proliferative, stimulate angiogenesis, and begin to 
form a metastatic tumour (adapted from Pantel et al, 1999). 
2.3.2. Causes of CMM 
Most melanomas are caused by Ultra-violet (UV) radiation damaging the DNA 
within the epidermal cells. The UV light causes molecules to become excited 
which leads to the formation of a covalent link between adjacent pyrimidines on 
a single strand of DNA. While most faults are repaired by DNA repair enzymes, 
occasionally this link may lead to a point mutation in DNA. If the affected DNA 
sequence happens to fall within the regulatory region of a gene controlling cell 
proliferation or apoptosis, it leads to the uncontrolled production of cells, and a 
tumour (King, 1996; Pantel eta/., 1999). 
Only 10% of CMM cases are hereditary (Fountain et a/., 1990). Dysplastic 
Nevus Syndrome (DNS) is an inherited syndrome thought to increase 
susceptibility to CMM. Affected patients possess 10-100 large nevi or moles 
which are at higher risk of becoming tumourigenic than normally pigmented skin 
(Bale eta/., 1986; Greene eta/., 1985). 
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Another precursor of CMM is a congenital nevus, present at birth as a brown or 
black, round or oval plaque. Statistics show that 40% of CMM cases seen in 
children arise from a giant congenital nevus (De lion et a/., 1976; Quaba and 
Wallace, 1986). 
2.3.3. Classification and prognosis 
Clinicians use several methods for staging of CMM, to compare prognosis with 
disease severity. Breslow's system of classification of CMM was developed in 
1975 and is still used as a major prognostic tool. This classification system is 
based on the vertical depth of the lesion as shown below in table 2.1 (Breslow, 
1975). 
Table 2.1. Breslow's system of tumour grading/prognosis (Breslow, 1975). 
Total thickness of tumour Five year survival rate 
0.00-0.76 mm 98-99% 
0.76-1.49 mm 85% 
1.50-2.49 mm 84% 
4.00 mm 44% 
Another important system of classification was developed by Clark et al (1975). 
In this .. classification system a tumour is graded according to depth of invasion of 
atypical cells or inflammatory infiltrates in relation to cutaneous histologic 
structures. Prognosis is correlated to the anatomical level of local invasion as 
seen in table 2.2 below. 
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i ve year surviv 
on rate 
Lesion involves only 
Levell epidermis (also called in- 98-100% 
situ melanoma 
Lesion invades the 
Level II papillary dermis, but does 72-96% 
not reach the papillary-
reticular dermis 
Invasion fills and expands 
Level Ill the papillary dermis, but 46-90% does not penetrate the 
reticular dermis 
Lesion invades into the 
Level IV reticular dermis, but not 31-67% into the subcutaneous 
tissue 
Invasion spreads through 
LeveiV the reticular dermis into 12-48% 
the subcutaneous tissue 
More recently the American Joint Committee for Cancer (AJCC) has outlined a 
classification system which takes into account the micro staging of the primary 
melanoma as well as clinical and radiological evaluation of regional lymph 
nodes and pathological evaluation of distant metastases (Balch et al, 2001 ). 
Prognosis of a patient is closely re!ated to the clinical stage of melanoma 
development as seen in table 2.3 below. 
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Table 2.3. AJCC system of tumour grading/prognosis (Balch eta/., 2001 ). 
ll· A~~~ Details of classification IJ ~·Five y"*""' II IIC 1•rviva1. 
Tumour in situ AND no regional 
Stage 0 lymph metastasis, no distant >95% 
metastasis. 
Tumour ~ 1.0mm thick & Clark level 
Stage lA I or II with no ulceration AND no >95% 
regional lymph metastasis, no 
distant metastasis 
Tumour~ 1.0mm thick & Clark level 
IV or V with ulceration OR tumour 
Stage IB >1.0mm but~ 2.0mm thick with no 89-91% 
ulceration AND no regional lymph 
metastasis, no distant metastasis 
Tumour >1.0mm but~ 2.0mm thick 
with ulceration OR tumour > 2.0mm 
Stage IIA but ~ 4.0mm thick with no ulceration 77-79% 
AND no regional lymph metastasis, 
no distant metastasis 
Tumour> 2.0mm but~ 4.0mm thick 
with ulceration OR tumour > 4.0mm 
Stage liB thick with no ulceration AND no 63-68% 
regional lymph metastasis, no 
distant metastasis 
-· 
Tumour >4.0mm thick with 
Stage IIC ulceration AND no regional lymph 44-46% 
metastasis, no distant metastasis. 
Tumour any thickness with or 
Stage Ill without ulceration AND metastasis 25-70% in 1 or more regional lymph nodes, 
.. no distant metastasis 
Tumour any thickness with or 
Stage IV without ulceration AND metastasis 5-10% in 1 or more regional lymph nodes 
AND distant metastasis 
These staging systems draw attention to the fact that once a tumour has 
metastasised, the five-year survival rate of the patient significantly decreases. 
As a result, studies involving the early identification of melanoma spread are of 
great importance in this field. 
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2.4. Melanoma detection 
2.4.1. Detection of primary tumours 
In order to reduce the incidence of melanoma, national Australian health 
campaigns have urged citizens to understand the ABCD method of melanoma 
detection; that is to observe any Asymmetry, and changes in the Border, Colour 
or Dimension of a skin lesion or mole. This is a clinical guide for the diagnosis of 
early stage melanoma which is important as the early excision of a thinner 
lesion leads to a better prognosis for the patient (Bono eta/., 1999). 
Once a lesion has been identified as possibly being at an early clinical stage 
melanoma, a biopsy is performed and examined macro- and microscopically for 
morphological evidence of melanoma (Holder et a/., 1998). 
Immunohistochemistry is performed on the sample to confirm the presence of 
tumourigenic melanoma cells. 
Primary antibodies used in immunohistochemistry assays include antibodies to 
melanoma specific markers such as MART-1/Melan-A (A103, M2-7C10, M2-
9E3 antibodies) and gp1 00 (gp1 DO-recognizing antibodies are HMB45 and 
NK1-beteb), and occasionally Tyrosinase (T311 antibody) or MITF (C5+D5 
antibodies) (Steingrimsson eta/., 2004). 
2.4.2. Detection of circulating melanoma cells 
Once CMM cells become invasive, they have the ability to infiltrate surrounding 
lymph and blood vessels. At early stages of metastasis, rpalignant melanoma 
cells are found in the sentinel lymph nodes, a factor which significantly 
decreases five-year survival rates for patients (Balch eta/., 2001 ). 
Interestingly, malignant melanoma cells can be detected in patient sera at all 
stages of the disease, but the level of spread may be dependent on both the 
quantity of circulating cells, their ability to evade the immune system, and their 
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ability to invade tissue (Ulmer eta/., 2004). Techniques have been developed 
that can quantify the nurnber of tumour cells present in patient peripheral blood 
and it is thought that this may be used as an indicator of disease spread (Hoon 
et a/., 2000; Palmieri et a/., 1999). However this remains to be fully elucidated 
as the tendency of these cells to become metastatic remains largely 
unexplored. The possibility that particular cells have a greater ability to 
metastasise than others is a crucial issue that remains to be resolved by a 
sample blood test. 
2.4.3. Marker detection techniques 
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a procedure 
which creates eDNA from mRNA (in this case isolated from cells in peripheral 
blood) followed by amplification of a sequence within a specific gene of interest. 
Using RT-PCR to target genes specific to melanoma cells, detection of the cells 
in peripheral blood is possible. RT-PCR has been used in laboratory research 
to detect melanoma cells in this way since 1991 (Smith et a/., 1991 ). The 
sensitivity of this technique has been well demonstrated; one tumour cell can be 
detected amongst 106-107 normal cells, but quality control for diagnostic use 
remains a problem due to the potential for both false positive and false negative 
results (Ghossein and Bhattacharya, 2000). 
Since melanomas are highly heterogeneous with respect to tumour-related 
gene expression, multi-marker RT-PCR has been developed (Medic et a/., 
2007). This procedure uses the simultaneous detection of several markers to 
allow for the expression of a variety of mRNA transcripts in CMM cells (Hoon et 
a/., 2000; Reynolds eta/., 2003). Multi-marker RT-PCR potentially overcomes 
the problem of false negative results as a variety of markers can be chosen that 
reflect different biochemical and pathological events characteristic of melanoma 
cells in general (Hoon eta/., 1995). As a result, identification of melanoma cells 
is more frequent in multi-marker analysis than in individual marker trials 
(Reynolds eta/., 2003). When combined with RT-PCR, multi-marker analysis 
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can be used to compare marker expression between patients possibly providing 
an estimate of tumour progression. 
Circulating melanoma cells can be detected in patient sera at all stages of the 
disease, but the ability of these cells to metastasise may depend on the number 
of circulating cells (Ulmer eta/., 2004). Recent studies utilising multi-marker RT-
PCR indicates that a higher number of markers are detected in peripheral blood 
of patients with more advanced stages of CMM. In addition, low risk of disease 
recurrence is associated with an absence of detectable markers in the 
peripheral blood of CMM patients who have undergone treatment (Hoon et a/., 
2000; Palmieri eta/., 1999; Wascher eta/., 2003). Alternately, markers may be 
identified in the future, that are characteristic of a more metastatic cell. 
2.5. Genetic markers of melanoma formation 
Survival and differentiation of normal melanocytic cells is tightly regulated by 
several signaling pathways. In melanoma however, aberrant increase or 
decrease in expression of any of the genes in these pathways may lead to 
tumour progression (Wagner and Fisher, 2005). Also, the invasion and spread 
of melanoma cells is associated with changes in cell adhesion as well as the 
increased ability of cells to proliferate (Miller and Mihm Jr, 2006). 
Markers of great interest in the detection of circulating melanoma cells in 
peripheral blood include genes involved in melanocyte differentiation and 
adhesion. Similarly, genes controlling cell proliferation and survival are required 
for the growth of a tumour to the invasive stage, making these genes possible 
markers of melanoma cell once they have entered the blood. Markers trialled in 
this study included those involved in melanocyte biology, development and 
survival such as PAX3d, SFRP5, MART1 and MITF and those regulating cell 
proliferation and invasive potential like TGF{32. 
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2.5.1. MITF expression in melanoma 
MITF is a master regulator of melanocyte differentiation, proliferation and 
survival. As a result, abnormal expression of this transcription factor may result 
in the uncontrolled replication of immortal melanoma cells, possibly leading to 
tumour progression (Wagner and Fisher, 2005). 
MITF contributes to melanocyte survival by increasing the expression of the 
anti-apoptotic gene BCL2. It does this by occupying the M-Box sequence 
located in the BCL2 promoter region (Figure 2.6) (McGill et a/., 2002). In 
melanoma cell lines, a decrease in BCL2 protein causes cell death, indicating 
that the survival of melanoma cells is dependent on BCL2 (Banerjee, 2002) and 
consequently on MITF. 
&1 ..__ /......., 
:r.un~ primers 
Figure 2.6. MITF M-Box sequence in the promoter region of BCL2 (Adapted from McGill eta/, 2002). 
MITF also acts as a pro-proliferation factor by up-regulating cyclin-dependent 
kinase 2 (CDK2) and t-box transcription factor 2 {TBX2) in melanoma. CDK2 is 
requir~d for cell proliferation, and is specific to melanoma (Du et a/., 2004). 
TBX2 is required to maintain proliferation and suppress senescence via down-
regulation of p21 in melanoma (Vance et a/., 2005). Thus MITF may be an 
important marker of melanoma progression. 
2.5.2. PAX3 expression in melanoma 
For melanoma cells to metastasise, they need to migrate and adhere to distant 
sites to form micrometastases. PAX genes have been observed to affect cell 
surface molecules and thus have a role in the regulation of cell motility and 
adhesion (Blake and Ziman, 2005; Scholl eta/., 2001; Ziman and White, 2006). 
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During development PAX3 regulates proliferation and migration of 
melanoblasts, while mai~taining the cells in an undifferentiated state. Once the 
cells reach their destination in the dermis, the cells differentiate and PAX3 is 
down-regulated, and remains down-regulated in the adult (Lang eta/., 2005). In 
melanoma cells however, PAX3 expression is de-regulated possibly causing the 
de-differentiation of melanocytes while promoting cell proliferation and migration 
(Lang eta/., 2005; Scholl eta/., 2001). This function of PAX3 may be implicated 
in melanoma metastasis (Blake and Ziman, 2003). 
PAX3 is highly expressed in melanoma; but not in normal tissue or normal skin 
aside from skin stem cells (Scholl eta/., 2001 ). During development, PAX3-c 
and PAX3-d transcripts control melanocyte differentiation and migration (Blake 
and Ziman, 2005). Interestingly, CMM cells predominantly express the PAX3d 
transcript indicating that it may be PAX3d aberrant expression that is important 
in melanomas (Barret a/., 1999; Medic, 2006). Thus PAX3d would make a good 
marker of melanoma cells in peripheral blood. 
2.5.3. MART1 expression in melanoma 
Melan-A/MART1 (hereafter referred to as MART1) is an antigen produced by 
the MLANAIMART1 gene (hereafter. referred to as MART1). It is involved in 
melanosome ontogeny; however its precise function is not known (Medic eta/., 
2007). MART1 is transcriptionally regulated by MITF, with MITF consensus 
recognition sites found in the promoter region of the gene as shown previously 
in Figure 2.1 b (Duet a/., 2003). 
MART1 is frequently expressed in melanoma tumour cells and melanoma cell 
lines, but is not expressed in non-melanoma malignancies or in the blood of 
humans without cancer (Wascher et a/., 2003). Several studies have 
investigated the relationship between the presence of MART1 in patient sera 
and the stage of melanoma progression. The frequency of detection was found 
to increase significantly with advancing stage of melanoma (Keilholz et a/., 
2004). 
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2.5.4. SFRP expression in melanoma 
The ability of SFRP to facilitate or impede WNT signaling allows it to control 
important signaling pathways. At high levels, SFRP acts as an antagonist to 
WNT/Frizzled interaction, blocking production of 13-catenin; at low levels, it up-
regulates 13-catenin (Polakis, 2000). As well as binding with LEF1 to allow the 
transcription of MITF, 13-catenin also plays a crucial role in the regulation of the 
growth of melanoma cells, with its down-regulation associated with increased 
tumour thickness and disease progression (Kageshita et a/., 2001 ). Thus, by 
regulating 13-catenin, SFRP functions to regulate melanoma progression making 
it an important marker in the detection of melanoma cells in peripheral blood 
and possibly a key indicator of disease progression. 
Low levels of expression of SFRP have been observed in breast, kidney and 
ovarian cancers, revealing a relationship between these proteins and cancer. 
The most likely SFRP family member to have an effect on the metastasis of 
malignant melanoma is SFRP5 which is expressed in epithelial cells, such as 
retinal pigment epithelium (Jones and Jomary, 2002). 
2.5.5. TGF{J expression in melanoma 
Pathways that activate cell proliferation and cell cycling are important features 
of both development and tumourgenesis. During development, Transforming 
Growth Factor Beta (TGF-13) is involved in the process of neural tube closure 
due to its control of cell proliferation (Sanford et a/., 1997). 
The TGF-13 signaling pathway is shown below in Figure 2.7. This pathway 
implicates TGF-13 as a regulator of many genes and transcription factors 
responsible for cell apoptosis and neogenesis (Mulder, 2000). In recent in vivo 
studies, TGF{32 was expressed in malignant melanoma cells but not found to be 
associated with normal melanocytes; it was therefore determine to be a critical 
factor in the development of deep invasion and metastasis in malignant 
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melanoma (Reed et a/., 1994 ). These findings indicate its potential as a 
valuable marker for use in the detection of melanoma cells in the blood. 
Figure 2.7. TGF-~ pathway controlling gene transcription and growth inhibition. TGF-~ attaches to a cell 
receptor and activates Ras and Smad proteins. These proteins then follow a signaling pathway leading to 
the activation of Smad4 and Erk, genes responsible for gene transcription, growth inhibition and apoptosis 
(Adapted from Mulder, 2000). 
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3. SUMMARY AND THEORETICAL FRAMEWORK 
The metastasis of CMM is responsible for a dramatic increase in mortality of 
patients with the disease. Consequently, studies focussing on the early 
detection of metastasis are essential. Since the advent of the Reverse 
Transcriptase Polymerase Chain Reaction (RT-PCR), many studies have 
analysed the use of molecular markers for the detection of melanoma 
metastasis (Lewis eta/., 2005; Smith eta/., 1991). 
Several molecular markers have been identified as reliable indicators of 
melanoma progression (Medic et a/., 2007). These markers have been studied 
individually and in groups using multi-marker RT-PCR. However the ideal 
combination that accurately predicts disease outcome has yet to be identified. 
Accordingly, further investigation to find an optimal array of markers is 
warranted. 
In this study, several markers have been trialled with RT-PCR. Multi-marker RT-
PCR allows the comparison of the expression of these markers in peripheral 
blood from patients with CMM of different primary tumour depths. Results were 
compared with peripheral blood of normal healthy volunteers to determine 
which of these markers would be suitable for use in a predictive and/or 
prognostic blood test of Cutaneous M?lignant Melanoma. 
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4. HYPOTHESIS AND AIMS 
4.1. Hypothesis 
PAX3d, MITF, SFRP5, MART1 and TGF-~2 are involved in formation 
and development of CMM and can be used as markers in the diagnosis and 
prognosis of CMM. 
4.2.Aim 
OVERALL AIM: 
To develop an assay that can be used for CMM diagnosis and prognosis. 
AIM: 
To detect PAX3d, MITF, SFRPS, MART1 and TGF-{32 expression in 
peripheral blood of patients diagnosed with malignant melanoma and to 
compare this expression with that found in blood from healthy volunteers. 
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5. MATERIALS AND METHODS 
5.1. Experimental Design and Procedures 
5.1.1. Collection of human tissue and blood samples 
All procedures performed as part of this study were ratified by the Faculty of 
Computing, Health and Science Human Research Ethics Committee (Appendix 
A) and conformed to NHMRC guidelines as stated on the website 
(http://www.nhmrc.gov.au/funding/policy/researchprac.htm). All tissues and 
blood samples were obtained from patients· identified by clinicians, and from 
whom informed consent was obtained. Blood samples were also obtained from 
healthy volunteers who were classified as melanoma free by clinicians or were 
undiagnosed but regarded as disease free based on self assessment. Healthy 
volunteers also signed consent forms allowing the use of their blood in the study 
(Information sheet and consent form are Appendix Band C, respectively). 
Lymph node tissues were obtained from melanoma patients by surgical removal 
for diagnostic and treatment purposes. Only tissues that were extraneous to the 
diagnostic procedure were used. Tissue was immediately cryopreserved in 
liquid nitrogen following excision and stored at -80°C prior to use. 
Blood. samples from patients or healthy volunteers were obtained by venous 
puncture and blood was collected in an EDTA tube (to eliminate melanocyte 
contamination from the site of injection), and then in a specially formulated RNA 
blood collection tube was (5-1 Oml). Each sample was subjected to RNA 
isolation within a week of being collected, and the RNA was stored at -80°C 
until used. For each patient blood sample, the depth of tumour and the time 
since surgical removal of the primary tumour, as indicated by the pathological 
reports, was recorded in an excel spreadsheet coded by number so that no 
private details were recorded. 
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5.1.2. Total RNA isolation from freshly isolated cryogenically preserved 
tissue 
Total RNA was extracted from frozen tissue samples using Aurum Total RNA 
Mini Kit (Bio-Rad, 732-6820) according to the manufacturer's instructions. 
Approximately 20-30mg of tissue was cut from the frozen lymph node sample 
and crushed under liquid nitrogen using a mortar and pestle. The tissue powder 
was then placed into a sterile RNase-free eppendorf tube and allowed to thaw 
before 7001JI of Lysis Solution was added. The lysate was mixed well, 
centrifuged for three minutes at 14,000rpm and the resulting supernatant was 
transferred into a fresh eppendorf tube. 
Following that, 7001JI of 60% ethanol was added to the tissue lysate, mixed well 
and 7001JI of the whole lysate was transferred to the RNA extraction column and 
centrifuged for 60 seconds at 14,000rpm, after which the filtrate was discarded. 
This procedure was repeated for the remainder of the lysate. Low Stringency 
Solution (700!-11) was added to the column, centrifuged for 30 seconds at 
14,000rpm and the filtrate was discarded. DNase Mix (801JI; 51JI DNase I and 
751JI DNase Dilution Solution) was added to the membrane of the column and 
incubated for one hour at room temperature and then centrifuged for 30 
seconds at 14,000rpm. The sample was washed with 7001JI of High Stringency 
Solution, centrifuged for 30 seconds at 14,000rpm. A second wash of 7001JI of 
Low Stringency Solution was added and centrifuged for 30 seconds. Additional 
centrifugation for one minute was performed to eliminate the remaining ethanol. 
The column was transferred into a fresh eppendorf tube and 251JI of Elution 
Solution, previously warmed to 70°C, was added to the membrane and allowed 
to saturate for one minute after which time it was centrifuged for 2 minutes at 
14,000rpm. The eluted total RNA was aliquoted and stored at -80°C until used 
for RT-PCR. 
28 
5.1.3. RNA extraction from peripheral-blood samples 
Blood was collected into PAXgene blood collection tubes (PreAnalytiX, 762165) 
and the RNA was extracted using a PAXgene Blood RNA Kit (Qiagen, 762132) 
according to the manufacturer's instructions described below. Additional DNase 
treatment with DNA-free (Ambion, AM-1906) was required after RNA isolation 
as genomic DNA was still present in the majority of the samples. 
Blood samples collected in PAXgene tubes were incubated at room 
temperature for at least 2 hours to allow optimal lysis of cells. The blood was 
then centrifuged at 2,800rpm for 10 minutes and the supernatant was decanted. 
RNase-free water (4ml) was added to the tube and the pellet was resuspended 
by thorough mixing, then the tube was re-centrifuged at 2,800rpm for 10 
minutes. The supernatant was then discarded and 3501-JI of Resuspension 
Buffer BR1 was added to the pellet. The sample was vortexed until the pellet 
dissolved, then transferred into a fresh microcentrifuge tube. Binding Buffer BR2 
(3001-JI containing guanidine thiocyanate) and Proteinase K (401-JI) were added 
to the lysate, mixed and incubated for 10 minutes in a shaker-incubator at 55°C. 
Following incubation, the lysate was transferred into a shredder spin column 
and centrifuged at 14,000rpm for 3 minutes. The supernatant was transferred 
into a fresh tube and 3501-JI of 100% ethanol was added and mixed. The lysate 
was transferred into a spin column a~d centrifuged for 1 minute at 14,000rpm 
then transferred to a fresh processing tube and the flowthrough was discarded. 
Wash Buffer BR3 (3501-JI containing guanidine thiocyanate and ethanol) was 
added to the column, centrifuged at 14,000rpm for 1 minute and the flowthrough 
was discarded. DNase I (101-JI, RNase-free DNase Set, Qiagen, 79254) arid 
701-JI Buffer ROD (RNase-free DNase Set, Qiagen, 79254) were gently mixed 
and added to the column membrane. The column was then incubated for 15 
minutes at room temperature and Buffer BR3 (3501-JI) was again added to the 
column and centrifuged for 1 minute at 14,000rpm, after which the flowthrough 
was discarded. The column was transferred into a fresh 2ml processing tube 
and 2x 5001-JI of Buffer wash BR4 containing 100% ethanol were added, then 
the tube was centrifuged for 1 minute once and a second time for 3 minutes at 
14,000rpm. The flowthrough was discarded and the column centrifuged for 1 
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minute at 14,000rpm to ensure complete removal of ethanol. The column was 
then placed into a fresh. 1.5ml eppendorf tube and 40~1 of elution Buffer BR5 
was added directly to the column membrane and the column was centrifuged at 
14,000rpm for 1 minute. The eluted RNA was incubated at 65°C for 5 minutes 
and immediately chilled on ice. 
RNA from the blood samples was then retreated with DNase I (DNAfree, 
Ambion) to completely eliminate genomic DNA, as follows: RNA samples at 
concentrations less than 200ng/~l were treated with 1 ~I of rDNase I and those 
at higher concentrations, with 2-3~1 of rDNase I. Reaction mixture containing 
rDNase I and 0.1 volume of 1 Ox DNase I Buffer and water to a total volume of 
30-50~1. was incubated for 30 minutes at 37°C. 1 x volume of resuspended 
DNase Inactivation Reagent was added and the reaction mixture incubated for 
2 minutes at room temperature with occasional mixing. Samples were then 
centrifuged for 1.5 minutes at 14,000rpm. The supernatant, containing RNA, 
was aliquoted into RNase-free tubes and stored at -80°C until used in RT -PCR 
reactions. 
5.1.4. Assessment of RNA quality and quantity 
The integrity of RNA was assessed o.n a 1% agarose gel by electrophoresis at 
100mV for 30 minutes in TAE Buffer. The gel was stained with ethidium 
bromide and visualised under UV light and results were recorded using the 
GeiDoc system (Bio-Rad). RNA samples of poor quality, defined by a lack of 
two clear ribosomal RNA bands, were excluded from further analysis. RNA 
concentration was determined by UV spectrophotometry and optical density 
recorded at 260nm and 280nm so that a ratio of 260:280 was obtained. 
Samples with an optical density ratio of 260:280 <1.8 were discounted. RNA 
concentration was calculated using the following formula: 
!concentration= Abs2ao x 40ng/~1 x Dilution Factod 
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5.1.5. RT -PCR analysis of gene expression 
Two-step Reverse Transcriptase PCR (RT-PCR) was used to assess the 
expression of PAX3d, MITF, MART1, SFRP5 and TGF{32 in blood and tissue 
samples obtained from CMM patients and healthy volunteers. The total 
numbers of samples used are detailed in table 5.1 below. 
T bl 5 1 Bl d d t' a e .. oo an 1ssue samples use d f RT PCR I . or - ana1ys1s 
Sample type Number 
Healthy volunteer peripheral blood 33 
CMM patient lymph node metastases 4 
CMM patient peripheral blood 68 
Healthy volunteer peripheral blood was used to critique all markers. The 
presence of a marker in healthy volunteer blood could indicate a false positive 
result, or a non-informative marker. With this information, the rate of false 
positives or the number of informative markers can be estimated from the 
general population and thus compared with results from CMM patients. 
CMM patient lymph nodes were used as positive controls as these tissue 
samples are known to contain melanoma cells. For each set of PCR reactions, 
eDNA obtained from any one of these lymph nodes was used as a positive 
reacti()n control. Negative control samples containing no template eDNA were 
used in each set of reactions to ensure there was no contamination of stock 
solutions. 
CMM patient peripheral blood was analysed to determine marker presence in 
the blood and to assess the relationship between marker expression, depth of 
tumour (disease progression) and time since removal of the primary tumour. 
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5.1.6. Two-step RT -PCR 
Two-step Reverse Transcriptase PCR consists of two phases: total eDNA 
synthesis from total RNA followed by PCR amplification of specific genes. This 
method of RT -PCR was preferred over one-step RT -PCR, which completes 
both phases in a single reaction, as the two-step method allows each sample to 
be tested for multiple genes, including GAPDH (as a measure of RNA integrity). 
Thus each sample was first reverse transcribed and then a PCR reaction was 
performed to assess GAPDH expression. 
5.1.6.1. Step one: Reverse transcription (RT) 
eDNA synthesis was performed using Omniscript Reverse Transcription kit 
(Qiagen, 205111 ), according to the manufacturers' instructions. 
Total RNA (250ng) was reverse transcribed in a 201-11 reaction mixture 
containing: 1x Buffer RT, 0.5mM each dNTP (Fisher Biotec, DN-25-1 00), 11JM 
Oligo-dT primer (Qiagen, 79237), 10 units of RNase OUT Recombinant 
Ribonuclease Inhibitor (Invitrogen, 1 0777-019), 4 units of Reverse 
Transcriptase and RNase-free water. The reaction was then incubated for 1 
hour at 37°C, followed by 5 minutes .incubation at 95°C followed by cooling at 
4°C. Following this procedure, samples were either used immediately in a PCR 
reaction, or stored at -20°C until used. 
5.1.6.2. eDNA analysis using GAPDH as a housekeeping gene 
To ensure that the RT process had been completed successfully, PCR 
amplification of GAPDH was completed for each sample using the reaction 
mixture described.below (section 5.1.6.3.), and the following cycling conditions: 
an initial PCR activation for 3 minutes at 94°C, followed by 3-step cycling 
process: Denaturation at 94°C for 45 seconds; annealing at 50 °C for 45 
seconds; extension at 72°C for 45 seconds repeated 40 times, before a final 
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extension at 72°C for 10 minutes. The reaction used Taq DNA Polymerase 
(Qiagen, 201205) and thE:} following primers: 
Fwd: 5' GGGTGTGAACCATGAGAA 3' 
Rev: 5' GACTGTGGTCATGAGTCCT 3' (Takeuchi eta/., 2003) 
The GAPDH forward primer is located in exon 6 at position 474-493 of human 
GAPDH mRNA, and the reverse primer is at position 607-591 spanning exons 7 
and 8 (GenBank accession number NM_002046). These primers amplify a PCR 
product of 134bp. 
PCR reaction products were assessed by agarose gel electrophoresis, and only 
following identification of the PCR product was the sample accepted for further 
analysis involving PCR amplification of selected genes. 
5.1.6.3. Step two: PCR amplification to detect presence of specific markers 
PCR was performed using Taq DNA Polymerase (Qiagen, 201205) and gene 
specific primers. Primers for gene amplification were designed and analysed 
using PrimerSelect software (DNASTAR, Lasergene ). All primers were 
subjected to BLAST analysis (NCBI) to ensure they did not bind elsewhere in 
the human genome. 
Primers: 
PAX3d (fwd) 
PAX3d (rev) 
MITF (fwd) 
MITF (rev) 
MART1 (fwd) 
MART1 (rev) 
SFRP5 (fwd) 
SFRP5 (rev) 
TGF-{32 (fwd) 
TGF-{32 (rev) 
5' -AGACTGATTACGCGCTCTCC-3' 
5'-GGCTGCGAAGACCAGAAAC-3' 
5'-GCTT AACTCCAACTGTGAAAAAGAG-3' 
5'-GGGAAAAA TACACGCTGTGAGC-3' 
5'-ATGCCAAGAGAAGATGCT -3' 
5'-TCAAGGCTCTGTATCCAT -3' 
5'-CAGTGTGAGATGGAGCACAG-3' 
5'-CTCCTTATTCTTCTTGTCCCAGC-3' 
5'-AAAACAAGAGCAGAAGGCGAA TG-3' 
5'-ATGTGGAGGTGCCATCAA TACC-3' 
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The PCR reaction was performed in a total volume of 201JI containing: 1x PCR 
Buffer (or Coralload PCR Buffer), 1x Q Solution, 0.2mM of each dNTP, 2.5 
units of Taq, 0.41JM of both the forward and reverse primers, PCR grade water 
and 21-11 of template eDNA (obtained from 250ng of Total RNA). 
The following cycling conditions were used: an initial PCR activation for 3 
minutes at 94°C, followed by 3-step cycling process: Denaturation at 94°C for 
30 seconds; annealing at 56°C of PAX3d, 57°C for MITF, 46°C for MART1, 
60°C for SFRP5 and 64°C for TGF-{32 for 30 seconds; extension at 72°C for 30 
seconds repeated 45 times, before a final extension at 72°C for 10 minutes. 
Although there is a very small risk of genomic DNA contamination of samples 
due to rigorous DNase treatments, the risk should not be ignored. Accordingly, 
the forward and reverse primers of each marker were located on different exons 
in order to allow the distinction between PCR amplicons from eDNA and 
genomic DNA due to the length of the PCR product. eDNA contains only exons; 
which are included in the mRNA sequence, whereas genomic DNA would 
contain introns between these exons and thus the resulting PCR product would 
larger. 
The forward primer for PAX3d is located in exon 8, position 1586-1605bp and 
the reverse primer is in exon 9, positi?n 1873-1855bp, of human PAX3 mRNA, 
(GenBank accession number NM_181458.1 ), and are designed to give a PCR 
product of 288bp. Exon 8 is contained in PAX3c, PAX3d and PAX3e transcripts, 
however the reverse primer in exon 9 recognises PAX3d and PAX3g transcripts 
only, thus together these primers amplify PAX3d exclusively. 
The MITF forward primer is located in exon 7, position 358-382bp and the 
reverse primer at position 694-673bp, spaning exons 11 and 12 of human MITF 
mRNA, (GenBank accession number NM_000248.2). These primers are 
designed to amplify a PCR product of 336bp. Although exon 7 is contained in 
MITF transcript variants 1, 2, 3, 4, 5 and 6, the reverse primer spanning exons 
11 and 12 recognises the MITF transcript variant 4 exclusively, which is also 
known as M/TF-M. 
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The MART1 forward primer is located in exon 2, position 54-71 bp and the 
reverse primer is in exon 3, position 225-208bp of human MLANA mRNA, 
(GenBank accession number NM_005511.1 ), and these primers are designed 
to give a PCR product of 171 bp. 
The forward primer for SFRP5 is located in exon 1, at position 728-747bp and 
the reverse primer is in exon 3, position 1051-1029bp of human SFRP5 mRNA, 
(GenBank accession number NM_003015.2), and these primers are designed 
to give a PCR product of 323bp. 
The forward primer for TGF{32 is located in exon 3, at position 752-774bp and 
the reverse primer is in exon 5, position 956-935bp of human TGF{32 mRNA, 
(GenBank accession number NM_003238.1 ), and these primers are designed 
to give a PCR product of 204bp. 
PCR products were analysed by 2% agarose-gel electrophoresis and ethidium 
bromide staining. Gels were run at 100 mV for 30 minutes in TAE buffer and 
PCR-product size was compared to pUC19 DNA ladder. PCR products were 
visualised and recorded using the Gel-Doc system (Bio-Rad). 
5.1. 7.- Sequencing of RT -PCR products 
Sequencing reactions were performed to confirm the identity of all RT -PCR 
products, checking that the PCR reactions amplified PAX3d, MITF, MART1, 
SFRP5 and TGF{32 respectively. 
Prior to sequencing, eDNA from the PCR reaction was cleaned using QIAquick 
PCR Purification Kit (Qiagen) according to the manufacturer's instructions. 
Briefly, 5 volumes of Buffer PB was added to 1 volume of PCR sample and the 
mixture was placed into the column and centrifuged for 30-60 seconds at 
13,000rpm. Buffer PE (750J.1I) was added to the column and centrifuged for 30-
60 seconds at 13,000rpm. The column was placed into a fresh tube and DNA 
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was eluted with 301JI ddH20 by centrifugation for 1 minute at 13,000rpm. This 
purification method was used to remove all PCR reagents and DNA fragments 
under 70bp in length, including primers. 
The BigDye Terminator v3.1 Cycle Sequencing Kit (AB Applied Biosystem) was 
used to sequence the amplicons. Sequencing reactions contained: 5ng of PCR 
product (approx. 300bp in length), 3.2 pmol of either the forward or the reverse 
primer, 2.5x Ready Reaction Premix and 5x BigDye Sequencing Buffer, diluted 
in ddH20 to a total reaction volume of 151JI. Sequencing cycling conditions 
were: 96°C for 3 minutes, then 30 cycles of 96°C for 1 0 seconds, rapid thermal 
ramp 1 0°C per second to 50°C, 50°C for 5 seconds and 60°C for 4 minutes. 
For the removal of excess dye terminators prior to sequencing, ethanol/sodium 
acetate precipitation of DNA was performed by addition of 501JI of precipitation 
mix (containing 1001JI of 96% ethanol, 21-11 3M Sodium-Acetate (pH 4.6), 4!-11 
0.1mM EDTA) and 51JI H20 to each completed sequencing reaction. After 
mixing and centrifugation for 20-25 minutes at 4,000rpm at 4°C, supernatant 
was discarded. Chilled 70% ethanol (1001JI) was added to each pellet prior to 
centrifugation at 4,000rpm at 4°C for 4 minutes. Supernatant was discarded and 
the resultant pellet was vacuum dried. Lyophilized DNA was wrapped in foil and 
kept at -20°C until analysed by the DNA sequencing service at Royal Perth 
Hospital (Perth) using an ABI Prism 3730 48 capillary sequencer. Resultant 
sequences were aligned with known sequences in GenBank using the 
multialign tool in the Angis computer program, available in GenBank. 
5.2. Statistical analyses 
All results were analysed using the Statistical Packages for the Social Science 
(SPSS) and its statistical analysis functions. 
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5.2.1. Presence of individual markers 
The efficacy of each marker was assessed separately by comparing the 
expression of each marker in CMM patients relative to its expression in healthy 
controls, with results statistically analysed using Chi-square or Fisher's Exact 
Tests. 
Following that, patients were allocated into groups dependent on the depth in 
millimetres of their primary tumour. Individual marker expression was assessed 
in relation to patient tumour depth, with results again statistically analysed using 
Chi-square or Fisher's Exact Tests. 
5.2.2. Presence of marker expression 
In order to assess the multi-marker assay as a whole, the expression of one or 
more markers was assessed in the CMM patients relative to healthy controls. 
This analysis allows the rate of positive identification of melanoma cells to be 
calculated in each group, assuming that the presence of one marker would 
indicate a positive result. Results were statistically analysed using Chi-square or 
Fisher's Exact Tests. 
5.2.3. Number of markers expressed 
Further statistical analysis of the multi-marker assay was performed to assess 
the number of markers expressed in the healthy control group compared with 
that of the CMM patient group. This analysis may lead to an insight into the 
number of markers necessary to conclude a true positive result (compared with 
a false positive in a healthy person). These results were statistically analysed 
using Chi-square or Fisher's Exact Tests. 
Additionally, the number of markers expressed in relation to CMM patient 
tumour depth was examined to determine whether primary tumour depth 
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influences marker expression. Results were statistically analysed using Chi-
square or Fisher's Exact Tests. 
5.2.4. Marker expression relative to time since diagnosis 
Individual marker expression and the number of markers expressed were 
analysed in relation to the time since diagnosis of CMM patients of in situ, 
S2.00mm and >2.00mm tumour depths. This analysis helps to determine 
whether markers would still present in the peripheral blood of a patient more 
than a year after diagnosis. Results were statistically analysed using Chi-square 
or Fisher's Exact Tests. 
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6.RESULTS 
6.1. Introduction 
This study used two-step Reverse Transcriptase PCR (RT-PCR) to identify the 
expression of PAX3d, MITF, MART1, SFRP5 and TGF/32 genes in the 
peripheral blood of healthy volunteers, and CMM patients with differing primary 
tumour depths. Melanoma tissue was used as a positive control. Positive 
expression is then assessed for association with CMM and regarded as arising 
from migrating melanoma cells. 
6.2. Samples 
154 patients from the private practice of Mr Robert Pearce at Hollywood 
Specialist Centre volunteered to donate one or more blood samples for use in 
this study. Of these, 150 were diagnosed with Cutaneous Malignant Melanoma, 
and 4 were non-melanoma patients. Overall, a total of 271 patient blood 
samples have been obtained. In instances where there were several blood 
samples available from a single patient, only one was used in this study. Five 
lymph nodes containing metastatic tumours were obtained from patients with 
metastatic melanoma, of which 4 were utilised in this study. A total of 33 healthy 
volunteer blood samples, for use as negative controls, were analysed in this 
study. 
6.2.1. CMM patient cohort 
68 blood samples from patients with CMM were analysed in this study. This 
cohort consisted of 45 (66%) males and 23 (34%) females, ranging in age from 
31 to 93 years; the median age was 77 years. The time between initial 
diagnosis and blood sample collection ranged from zero (collected at the time of 
diagnosis) to 4 years and 1 0 months. 
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Of the 68 patients, 20 (30%) were diagnosed with in-situ melanoma and of 
these, 11 (55%) were di~gnosed within one year prior to blood collection and 9 
(45%) were diagnosed more than one year prior to blood collection. Twenty-four 
of the 68 patients (35%) had a primary tumour depth of S2.00mm, of which 16 
(67%) were diagnosed within one year prior to blood collection and 8 (33%) 
were diagnosed more than one year prior to blood collection. The remaining 24 
(35%) of the 68 test patients had a primary tumour depth of >2.00mm and of 
these, 15 (62%) were diagnosed within one year prior to blood collection and 9 
(38%) were diagnosed more than one year prior to blood collection. The 
structure of the CMM patient cohort is analysed below in Table 6.1. 
For each in situ patient, the pathology report specified that their primary tumour 
was either in situ or Clarks level 1. Importantly, all in situ patients had a tumour 
depth of O.OOmm and for the purposes of this study they were analysed 
separately. The S2.00mm group refers to patients with a primary tumour depth 
of 0.01 mm-2.00mm. In this study, the >2.00mm group refers to patients with a 
tumour depth of 2.01-16.00mm. 
T bl 6 1 A I . f CMM f t h rt a e . . nalySIS 0 pa 1en co o . 
Time since diagnosis 
Depth of primary Total number of ::;1 year. >1 year. 
tumour patients Number of patients Number of patients 
In-situ 20 11 9 
::;2.00mm 24 16 8 
>2.00mm 24 15 9 
6.3. Quality assurance of eDNA product 
RNA was isolated from blood and tissue; its quality was assessed by agarose 
gel and its amount by optical density. Moreover, for use in the study, RNA was 
required to be of sufficient quality to successfully amplify the housekeeping 
gene GAPDH in an RT-PCR reaction. A PCR product, with an expected size of 
134bp indicating GAPDH expression, was obtained for all samples utilised. Any 
samples unable to amplify GAPDH were not used in the study; since the same 
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amount of eDNA was utilised in each reaction, the amount of PCR product for 
GAPDH expression was .the same. Figure 6.1 shows an example of the agarose 
gel analysis of several samples amplified to assess GAPDH expression. As a 
result of the positive identification of GAPDH, all RNA and subsequent eDNA 
was suitable for marker expression analysis by RT -PCR. 
+ p59 p67 p69 p70 p71 p77 p81 p83 pUC19 
Figure 6.1. 2% agarose gel showing PCR products amplified for analysis of GAPDH expression in CMM 
patient peripheral blood samples. p=CMM patient sample number, pUC19=pUC19 DNA ladder.- denotes 
negative control with no eDNA, + denotes positive control. 
6.4. Gel analysis of RT -PCR products 
Following the analysis of RNA quality, samples showing GAPDH expression 
were then analysed by RT -PCR for the presence of each of the genetic 
markers: PAX3d, MITF, MART1, SFRP5 and TGF/32. The agarose gel 
displaying the PCR products from some healthy volunteer samples analysed for 
MART1 is shown in Figure 6.2 and the agarose gel displaying the PCR products 
from some patient blood samples analysed for PAX3d is shown in Figure 6.3 
below. Since only presence or absence was recorded in this project, the level of 
expression of individual genes was not assessed relative to GAPDH. 
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pUC19 + h17 h23 h25 h26 h27 h28 h29 h30 h32 h33 
Figure 6.2. 2% agarose gel showing PCR products amplified to analyse MART1 expression in a 
representative set of control samples. h=healthy control samples, pUC19=pUC19 DNA ladder. - denotes 
negative control in which there was no eDNA,+ denotes positive control (lymph node eDNA). 
pUC19 + p59 p67 p69 p?O p71 p77 p81 p83 
Figure 6.3. 2% agarose gel showing PCR products amplified for the analysis of PAX3d expression in a 
representative set of patient samples. p=CMM patient sample number, pUC19=pUC19 DNA ladder. -
denotes negative control (no eDNA), +denotes positive control (lymph node eDNA). 
6.5. Marker sequencing reactions 
RT-PCR products from each marker were sequenced to confirm that the 
product was in fact the mRNA product produced from gene of interest. 
Sequenced PCR products were tested for GAPDH, PAX3, MITF, MART1, 
SFRP5 and TGF{32 and results were aligned with the corresponding NCBI 
mRNA sequences for each gene (detailed in section 5.1.6. above). 
The results were positive for each marker; that is, all PCR products aligned with 
their expected mRNA sequence as shown below in Figure 6.4. The number of 
base pairs aligned varies due to the different product size of each marker. 
GAPDH sequencing results aligned with its expected mRNA sequence 
cap 
seq 
Consensus 
m ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ 
I I 
GR&TCCIICT66C611:TTOICCIICOITGGflGflllliliCTG666CTCRTTT6l:ll6lililili6'&GTOlTom:ttTGCCCCCltTIU6AT&:CCCCAT6m:GTOlTGG6T6TGAACCAT6IIilllliT 
116TTTIIRATIITIIICCGNCCQII:IIIX~CCCCT --tTGG6T6TGAACOlT611i11AGT 
••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••···flirrl allaclllmtcGnCCmnCncC. ,.acnCCCCCaT ••••••• aTGGGTGTiiAACCIITIBiftAGT 
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ 
I I 
ATiiRCIIIICftGCCTOIIIGATCATillo:IIIITGCCTctTGCACCIIWI!CTGCTTillilliCCCCT6GCOIIIGGTOllllliTGAtiiiiCTTTG6TATCiiTQillfl6GACTCATiiiiCCIICII6TCCTGCCATlliCTGC 
ATiiiiCIIACAGCCTOIIGIITCATOIOCIIIITGCCTctTGCACCfiWIICTGCTTAC 
ATGACAACAGCCTCIIIIGIITCATCIIGCAATGCCTctTGCACCIIWI!CTGCTTIIc •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
PAX3d sequencing results aligned with its expected mRNA sequence 
pOMJd 
seq 
Consensus 
paxld 
.... 
Consensus 
1561 1570 1580 1590 1£00 1610 1620 1.530 1640 1650 1660 1670 1680 1G90 
I I 
CIICG6TllG6GTIIttTCAT~TTIIai:GCTCTa:cCTCT[11[£1;63GGTI:TGGRII[CTACCACOICGGTG-TCGGCCR6CTGCAGTCR6RGRCTIIGACCRT GRR6R6CTTGGIICIIG 
GG66CNG CRCCIICGGNG GGCCR6CTGCAGTCIIGRGACTRGACCATTRTGRRGR6CTTGGIICIIG 
•••••••••••••••••••••••••••••••••••••••••••••••••••••••• GGGcCnG . ARCCT . CCACCIICGGnG. TI:GGCCR6CTGCAGTCR6AGRCTIIGIICCRT . RTGRAGflll:TTGGACRG 
16S1 1700 1710 1720 1730 1740 1750 1760 1770 1780 1790 1800 1810 11120 
I I 
TCTGCCARCATCTCRGTCCTACTGTCCRCCCACCTRTAGCRCCIICAGGCTRCIIGTRTG611CCCTGTCIICAGGCTACCRRTATiiGGCFIGTRTGGRCAflfiGTGCCTTTI:RTTRTCTCRAGCCAGRTATCiitG 
TCTGCCARCRTCTCRGTCCTACTGTCCRCCCRCCTATAGCACCACRGGCTACR6TRTG611CCCTGTCIICRGGCTACCRRTRTGilGtAGTRTGGRCRRRGTGCCTTTCRTTRTCTCRRGCCAGRTRTCGCG 
TCTGCCARCRTCTCAGTCCTACTGTCCRCCCRCCTRTRGCACCACRGGCTRCR6TRTG611CCCTGTCIICAGGCTACCRRTRTiiGGCAGTRTGGRCAfiRGTGCCTTTCATTATCTCRR6CCAGRTATCGCG 
1821 1830 1040 1850 1860 1870 1080 1890 1900 1910 H20 1930 1940 1950 
I I 
TRAGTGAACTGTCCACTTG6RGCTRRRACTGGCCCTGTnCT6 TTCGCAGCCTAGRTRTGAA60ATCTGCTCTGIUWiCIUUUUUUUUI I I RCCCTTTTGTTiiliGGGGGiiTGGGGCA6T1iGTCCCMT 
TFIAGT6111CTGTa:RCTTG6AGCTARRHCTGGCCCT6TTTCT66CCTTCGCAGCCAAN6111NNN 
TAAGT6111CTGTCCRCTTG6AGCTAAARCTGGCCCTGTTTCT66cCTTCGCAGCCaRnaaflnna •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
MITF sequencing results aligned with its expected mRNA sequence 
ni.t.f 
... 
Consen3U3 
l'lit.f 
seq 
c~ 
..U.< 
..... 
c.....,._,. 
391 400 410 420 430 440 450 460 470 410 490 500 510 520 
I I 
TfiAGTTTGRfiGflliCAAfWIGGCRGAGA6Cm6TGCCC:AGGCATGARICACACATTCACGAGCGTCCTGTRTGCAGRTGGRTGRTGTAATCGRTGACATCATTAGCCTRGAATCAAGTTATAAT6AGGAA 
CNTCGGRGRGCGRIITCCCCRGGCRTGRACfiCRCATTCOCGAGCGTCCTGTATGCRGATGiiiiTGIITGTRATCGRTGIICIITCRTTRGCCTRGIIRTCAAGTTRTRATGRGGRR 
• ...................... • GnaCa GAGR6C6fln TGCCCRGGCRT6HMliCIICRTTCRCGA6C6TCC:TGTATGCft6HT66RTGRTGTfiRTCGHTiiiiCJITCRTTRGCCTR6ARTCflfiGTTRTRRT6fl6lifWI 
521 530 549 550 560 570 580 590 GOO G10 1&20 G30 G40 G50 
I I 
RTCTTGGGCTTGATGGRTCCTGCTTTGCAHHTGGCfiRHTRCGTTGCCTGTCTCGGGRRRCTTGfiTTGRTCTTTRTG6RRHttiiRGGTCTGCCCa:JIIXRGG:CTCACCRTCIIGCRRCTCCTGTCCRiiCCR 
ATCTTGGGCTTGRT6&fiTCCTGCTTTGCRfiRT68CRRRTRCGTTGCCT&TCTCGGGARRCTTGRTIGRTCTTTRTG6RflfiCOIRGGTCTGCCCCCIICCRGGCCTCRCCRTCROCRRCTCCTGTCCR&CCII 
RTCTTGGGCTTGATfimTCCTGCTTTGCAfiATGGCfiRRTACGTTGCCTGTCTCGGGAARCTTGATTGATCTTTATGGRAACCAAGGTCTGCCCCCACCAGGCCTCRCCfiTCAGCftACTCCTGTCCAGCCfl 
G51 660 670 680 li90 700 710 720 730 740 750 760 770 1110 
·----- ------1 ACCTTCCCRRCRTRRARNiGGRGCTCRCRtiC&T&TIITTTTTCCCRC TCT6fiiiGCARGRCCRCTGGCCRAAGRGRiiliii:AiiARRAR6GRCRRTCfiCAACCTGRT TGRACiillllliARGfiRGRTTTfiiiCIIT 
ACCTTCCCRRCRTRAIWWiGGRGCTCACR6CGTGTRTTTTTCCCR~TG---GM'iNTCCGCCRCCAGMGDICGTAn.GierlnCKMCIIIC6TTNGHGTNti..,.....__..CRCNCGGTTTIIill-ft 
fiCCTTCCCRACRTRfl~RGCTCRCRGCGTGTRTTTTTCCCR •• nRiinCTG .......... GaGnaCcGcCaaaRGa6anceaaaaaaaneaCa..:.C.acnena rnGaann .... naRcaaGa TTT aa .... n 
781 BOO 81.0 820 830 840 850 870 890 900 910 
MART1 sequencing results aligned with its expected mRNA sequence 
1 10 20 lO 40 50 60 70 80 !10 100 uo 120 130 
I I 
....-t1 T6Clllll6llGIIIITIUCACTTCRTCTIJT9ilT~fiGGCRCfiGCCRCTCTTRCACCRCGGCT6RAGRGGCCGCTGGGATCGGCRTCCTGACAGTGATCCTGG6AGTCITRCTGCTCRTCG6 
seq GGGC GGCCFICTCTTRCACCRCGGC16RRGRG6[[GC1GGGRTCGGCRTCCT611l!GTGATCCTGG6AGTCTTHCTGCTCHTCGG 
Conso:n= •••••••••••••••••••••••••••••••••••••••••••• GGGC . CGGCCACTCTTACACCACGIU6HAGII66CCGC1GGGATCGGCHTCCTGIIl!GTGATCCTGG6AGTCITACTGCTCATCG6 
rn ~ ~ ~ m w ~ ~ ~ ~ ~ ~ ~ ~ 
I -+----1 
n..-tl CTGTT6GTATTGTRGIIII6RCGIWITGGATRCRGIIGCCTTilHTG6ATHRRRiiTtTTCAT6IT6Gt8CTCIITT6TGctTTRACIII611161TTGCilliCIIfi6IIITTTGRTCIITCG6GACII6CH6TGTCT 
seq CTGTTGGTRTT6TR611116RCGIWITGGRTRCRGIIGCCTTGIIIIAN.._.....NCIIIICN 
["""""""' CTGIT6GTATTGTRGIIII6RCGIWITGGATRCRGAGCCTTGIIaananaoaannnnn[ annc:n ••••••••••••••••••••• •••• •••• •••••••••••••••••••••••••••••••••••••••• 
SFRP5 sequencing results aligned with its expected mRNA sequence 
sfrp 
seq 
Coo=nsus 
m ~ ~ 680 ~ 700 ~ = 730 ~ ~ ~ m ~ 
I I 
TGGIICIIIICGACC1TGOlTI:6CC6TGCII6TTCG66CIIttTiiCCC6CCIIIX6CGTGIIIXIIIIGHTCIGCGCCCAGT6T6AGIIT66HGCIICITGCT611C66CCTCRTGGIIGCII6fiTGTGCTCCRG 
. GTGCTCCNG 
••••••••••••••••••••••••••••••••••••••••••••••••••••• ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••GTGCTCCaG 
m ~ ~ ~ 1120 ~ 040 850 ~ ~ - - ~ m 
I - 1 
TGACTTTGTGGTCARAATGCGCATCIIII6EIIGATiliiiGATAGIGIATGGiimCC1i61116CTGATTGGRGCCC11611ARRAGIIIGAAGCT6C ICAAGU:GGGCt=TGAAGCGCRRGGIDICCAAGCGGCTG 
TGRCTTTGTGGTCRARATGCGCRTCIIIIi&RGRTiliiiGRTRGIGIRTGGG6ACCGGRII6CTGRTTGGAGCCC11611RRRRGIIIGRRGCT6CTOlAGU:GGGCt=TGARGCGCRRGGIDICCRRGCGGCTG 
TGACTTTGTGGTCAAAATGCGCATCHH66AGATiliiiGRTRGIGIRTGGG6ACCGGRII6CTGATTG6RGCCCII6IIflfiR861116RRGCTGCTCRRGU:6GGCCCCCTGRAGCGCRRGGfiCII[CflftGCI;GCTG 
911 920 9lO 940 950 960 970 980 990 1000 1010 1020 1030 1040 
I I 
GTGCT6CRCATGIIIIGARTGGC6CGGGCTGCCCCTGCCCACAGCTGGRCAGCCTGGC666CIIGCTTCCTGGTCATGGGCCGCIIIIAGTG6ATGGIICIIGCTGCTGCTCATGGU:6TCTACCGCTGGGHCRAGA 
GTGCTGCACRTGIIIIGAATGGCGCGGGCTGCCCCTGCCCACAGCTGGRCIIGCCTGGCGGGCAGCTTCCTGGTCRTGGGCCGCRIIRGTGGIITGGRCAGCTGCTGCTCRTGGU:GTCTACCGCTGGGHCRRGR 
GTGCTGCACATGIIIIGRRTGGCGCGGGCTGCCCCTGCCCRCAGCTGGRCAGCCTGGCGGGCAGCTTCCTGGTCRTGGGCCGCBRRGTG6ATGGACRGCTGCTGCTCRTGGU:6TCTACCGCTGGGHCRRGA 
1041 1050 1060 1070 1080 1090 1100 1110 1llO 1130 U40 1150 1160 U70 
I I 
AGRRTBRGGRGR1QtAGIIIQJI;f~TTOll6TTCTCCTIIIll:CT6CTCCCTCTHI:TACCCTTTCnCIIILbLLLLLbliLIIILIII6G6ULICCICCTT6CCCTGIDI6CTGT6CCTTG 
RGRATHRGG 
IIGRATBRGG 
TGF{32 sequencing results aligned with its expected mRNA sequence 
1 10 20 lO 40 50 60 70 110 !10 100 110 120 130 
I I 
~rfb ltlfiCIItitiCIU6111166CTCTctTTC6AT6TfiACTIJITGCTGTTCRTGIIIIT&l;CTTCACCRTAAAGRCAGGAACCTGGGRTTTIIIIIIIITfiiGCTTACACTGTCCCT6CTGCIICTTTTGTACCAT[ 
oeq GGTTCACCRTAAAGRCRGGAACCTGGGRTTTHRRATIIIGCTTACACTGTCCCTGCTGCIICTTTTGTACCRTC 
CcJnsenou& •••••••••••••••••••••••••••••••••••••••••••••• ••••••••••••GcTTCACCRTAAAGRCIIGGAACCTGGGAmiiiiAIITfiiGCTTACACTGTCCCTGCTGCIICTTTTGTACCATC 
= ~ ~ ~ ~ ~ ~ - ~ = = ~ ~ ~ 
I I 
~orfb TAATfiiTTACRTCATCCCIWITAARRGTGRAGIIACTAGAAGCIIIIGATTTGCAGGTATTGATGGCIICCTCCACRTATRC--cAGT66TGATI:ACIIfllfiCTATARAGTI:CACTAGGIIIIIIIIAfiRIICHG-
seq TAATARTTACRTCRTCCCIWITAAARGTGAAGRACTAGRRGCARGATTTGCAGGTATTGATGGCACCTCCACRTAAARIICIDICNGTTIITNCNCTGTTC~CCGCCTIINCNNGTWTCNGG TGNN 
Consensus: TRRTRATTACRTCATCCCMATAAAAGTGAAGAfiCTAGAAGCOOGATTTGCAGGTRITGRTGGCR:CTCCACftTAaAa ...... CaGT en T nenCa6aaaaCaanaaaccataCna(ic .. aaaaRaCaG •• 
42 
Figure 6.4. GAPDH, PAX3d, MITF, MART1, SFRP5 and TGF~2 RT-PCR product sequences aligned with 
their expected mRNA sequence. Red letters indicate base pairs that align between the RT-PCR product 
sequence and the mRNA sequence. 
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6.6. Presence of marker expression in CMM patient and healthy blood 
Due to the heterogeneity of CMM, it is understood that marker expression will 
vary between samples. The purpose of a multi-marker assay is to identify 
expression of at least one marker in all patient samples. Figure 6.5 shows the 
expression of one or more markers in the peripheral blood of CMM patients and 
healthy volunteers. Chi square analysis of expression of one or more markers 
as a percentage of the total number of samples, shows that the CMM patients 
express one or more markers significantly more frequently than healthy 
volunteers (Fisher's exact test: p=O.OOO,df=1; table 6.2). 
100 
Ill 80 
CJ) 
c. 60 E 
111 
Ill 40 
-0 
~ 0 20 
0 
Expression of one or more markers in blood samples from 
CMM patients and healthy volunteers 
Healthy Patient 
zero • one or more markers I 
Number of CMM patients and healthy volunteers· showing expression of zero markers and one or 
more markers 
Sample type Zero One or more markers 
Healthy 25 8 
Patient 15 53 
Figure 6.5. A graphical representation of the analysis of expression of one or more markers in blood 
samples from CMM patients, relative to healthy volunteers. * denotes a statistically significant difference 
between CMM patients and healthy volunteers. Table shows the total number of CMM patients and 
healthy volunteers expressing zero and one or more markers. 
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Table 6.2. Statistical analysis of expression of one or more markers in the peripheral blood of 
CMM patients relative to healthy volunteers (Chi-Square Tests). 
Asymp. Sig. Exact Sig. (2- Exact Sig. 
Value Df (2-sided) sided) (1-sided) 
Pearson Chi-Square 26.784(b) 1 .000 
Continuity Correction( a) 24.586 1 .000 
Likelihood Ratio 27.302 1 .000 
Fisher's Exact Test .000 .000 
Linear-by-Linear Association 26.519 1 .000 
N of Valid Cases 101 
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 13.07. 
6. 7. Expression of individual markers in CMM patient and healthy blood 
The number of CMM patient and healthy volunteer samples that were positive 
for each individual marker was analysed by SPSS. The percentage and number 
of samples positive for each marker is shown in Figure 6.6 below. It is important 
to note that in this graphical representation, the sum of the percentages of 
marker expression may exceed 1 00% for CMM patient and healthy volunteer 
groups as each sample may express more than one marker. Chi-square 
analysis, of marker expression as a percentage of the total number of samples, 
indicates that PAX3d and SFRP5 are not significantly differentially expressed in 
CMM patients relative to healthy volunteers. However MITF, MART1 and 
TGFf32 showed significantly higher expression in CMM patient samples than in 
healthy volunteer samples (Fisher's exact test: p=O.OOO,df=1 and p=O.OOO,df=1 
and p=0.001 ,df=1 respectively; table q.3). 
Individual marker expression in blood samples from CMM 
patients and healthy volunteers 
60 ~----------------------------------------------~ 
:g 50 
c. 40 
E 
~ 30 
0 20 
'#. 10 
0 +---
PAX 3d MITF 
p=O.OOO* 
MART1 SFRP5 TGF{32 
healthy • patient J 
Number of CMM patients and healthy volunteers showing expression of each marker 
Marker CMM patients Healthy volunteers 
PAX3d 17 3 
MITF 30 0 
MART1 33 3 
SFRPS 13 5 
TGF{32 17 0 
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Figure 6.6. A graphical representation of the analysis of individual marker expression in the peripheral 
blood of CMM patients relative to healthy volunteers. * denotes a statistically significant difference 
between CMM patients and healthy volunteers. Table shows the total number of samples expressing each 
gene in CMM patients and healthy volunteers. 
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Table 6.3. Statistical analysis of MITF, MART1 and TGF/32 expression in blood samples from 
CMM patients relative to healthy volunteers. 
Statistical analysis of MITF expression in CMM patients relative to healthy volunteers 
(Chi-Square Tests) 
Asymp. Sig. Exact Sig. Exact Sig. 
Value df _(2-sidedf (2-sided-) (1-sided-) 
Pearson Chi-Square 20.710(b) 1 .000 
Continuity Correction(a) 18.651 1 .000 
Likelihood Ratio 29.557 1 .000 
Fisher's Exact Test .000 .000 
Linear-by-Linear Association 20.505 1 .000 
N of Valid Cases 101 
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 9.80. 
Statistical analysis of MART1 expression in CMM patients relative to healthy volunteers 
(Chi-Square Tests) 
Asymp. Sig. Exact Sig. Exact Sig. 
Value df (2-sidedf (2-sided) (1-sided) 
Pearson Chi-Square 15.065(b) 1 .000 
Continuity Correction( a) 13.395 1 .000 
Likelihood Ratio 17.255 1 .000 
Fisher's Exact Test .000 .000 
Linear-by-Linear Association 14.916 1 .000 
N of Valid Cases 101 
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 11. 76. 
Statistical analysis of TGF/32 expression in CMM patients relative to healthy volunteers 
(Chi-Square Tests) 
Asymp. Sig. Exact Sig. Exact Sig. 
Value df (2-sidedf (2-sided) (1-sided) 
Pearson Chi-Square 9.920(b) 1 .002 
Continuity Correction( a) 8.214 1 .004 
Likelihood Ratio 15.070 1 .000 
Fisher's Exact Test .001 .001 
Linear-by-Linear Association 9.821 1 .002 
N of Valid Cases 101 
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.55. 
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6.8. Markers expressed in relation to patient tumour depth 
To assess the relationship between tumour progression and gene expression, 
patients were divided into groups dependent on the level of invasion and the 
depth in millimetres of their primary tumour, as indicated on their pathology 
report. Tumours were regarded as either in situ with a depth of O.OOmm, 
S2.00mm (spanning 0.01 mm-2.00mm in depth) or >2.00mm in depth (spanning 
2.01-16.00mm). Figure 6.7 indicates the expression of individual genetic 
markers in relation to the depth of the primary tumour of CMM patients. Again, 
the sum of the percentages of marker expression may exceed 1 00% as each 
patient may express more than one marker. Chi-square analysis of marker 
expression as a percentage of the total number of patient samples shows that 
CMM patients with a tumour depth S2.00mm are significantly less likely to 
express MART1 than patients with either in situ melanoma or >2.00mm tumour 
depths (Fisher's exact test: p=0.029,df=1 and p=0.001 ,df=1 respectively; table 
6.4). Additionally, CMM patients with a tumour depth >2.00mm were 
significantly more likely to express TGF{32 than patients with in situ melanoma, 
or S2.00mm tumour depth (Fisher's exact test: p=0.025,df=1 and p=0.003,df=1 
respectively; table 6.5). 
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PAX 3d MITF MART1 SFRP5 TGF{32 
I• in situ :52.00mm • >2.00mm I 
N b f f t "th . "t <2 00 urn er o pa 1en s WI tn Sl U,- . mman d 2 00 t >. mm umour d th ep1 s expressmg eac h k r mare 
in situ :52.00mm >2.00mm 
PAX3d 6 4 7 
MITF 12 8 10 
MART1 11 5 17 
SFRPS 3 6 4 
TGF{32 3 2 12 
Figure 6.7. A graphical representation of the percentage of CMM patients expressing each marker in 
relation to the depth of their primary tumour. * denotes a statistically significant difference between 
patients of differing primary tumour depth . Table shows the number of CMM patients with in situ, :52.00mm 
and >2.00mm tumour depths expressing each marker. 
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Table 6.4. Statistical analysis of MART1 expression in the peripheral blood of patients with 
:::s;2.00mm tumour depth in relation to patients with in situ or >2.00mm tumour depth. 
Statistical analysis of MART1 expression in the peripheral blood of patients with S2.00mm tumour 
depth in relation to patients with an in situ primary tumour 
(Chi square Tests) 
Asymp. Sig. Exact Sig. Exact Sig. 
Value df (2-sided) (2-sided) (1-sided~) 
Pearson Chi-Square 5.503(b) 1 .019 
Continuity Correction( a) 4.126 1 .042 
Likelihood Ratio 5.593 1 .018 
Fisher's Exact Test 
.029 .021 
Linear-by-Linear Association 5.378 1 .020 
N of Valid Cases 44 
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 7.27. 
Statistical analysis of MART1 expression in the peripheral blood of patients with S2.00mm tumour 
depth in relation to those with >2.00mm tumour depth 
(Chi-Square Tests) 
Asymp. Sig. Exact Sig. Exact Sig. 
Value df (2-sided) (2-sided) (1-sided) 
Pearson Chi-Square 12.084(b) 1 .001 
Continuity Correction( a) 10.154 1 .001 
Likelihood Ratio 12.670 1 .000 
Fisher's Exact Test .001 .001 
Linear-by-Linear Association 11.832 1 .001 
N of Valid Cases 48 
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 11.00. 
Table 6.5. Statistical analysis of TGF/32 expression in the peripheral blood of patients with 
:::s;2.00mm tumour depth in relation to patients with in situ or >2.00mm tumour depth. 
Statistical analysis of TGF/32 expression in the peripheral blood of patients with >2.00mm tumour 
depth in relation to patients with an in situ primary tumour 
(Chi square Tests) 
Asymp. Sig. Exact Sig. Exact Sig. 
Value df (2-sided) (2-sided) (1-sided) 
Pearson Chi-Square 5.948(b) 1 .015 
Continuity Correction( a) 4.492 1 .034 
Likelihood Ratio 6.285 1 .012 
Fisher's Exact Test .025 .016 
Linear-by-Linear Association 5.812 1 .016 
N of Valid Cases 44 
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 6.82. 
Statistical analysis of TGF/32 expression in the peripheral blood of patients with >2.00mm tumour 
depth in relation to those with S2.00mm tumour depth 
(Chi square Tests) 
Asymp. Sig. Exact Sig. Exact Sig. 
Value df (2-sided) (2-sided~) (1-sided) 
Pearson Chi-Square 10.084(b) 1 .001 
Continuity Correction(a) 8.168 1 .004 
Likelihood Ratio 10.910 1 .001 
Fisher's Exact Test .003 .002 
Linear-by-Linear Association 9.874 1 .002 
N of Valid Cases 48 
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 7.00. 
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6.9. Number of makers expressed in CMM patient and healthy blood 
In order to evaluate the number of markers that are diagnostically relevant in 
the multi-marker assay, the number of markers expressed per sample was 
examined in CMM patients relative to healthy volunteers. Figure 6.8 below 
shows the number of markers expressed in patients relative to those in healthy 
volunteers. Analysis shows that 75.8% of healthy volunteers shows no 
expression of markers, whereas only 22.1% of CMM patients expressed no 
markers, a significant difference (Fisher's exact test: p=O.OOO,df=1 - table 6.6). 
Moreover, patients were significantly more likely to express two and three or 
more markers than healthy volunteers (Fisher's exact test: p=0.021 ,df=1 and 
p=0.001 ,df=1 respectively; table 6.7). 
Number of markers expressed in CMM patients and healthy 
volunteers 
If) 
.!! 60 Q. 
E 
~ 40 
..... 
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";!. 
0 
Healthy 
p=0.021 
* 
patients 
1 marker • 2 markers [] 3 or rmre markers 
Number of CMM patients and healthy volunteers expressing zero, one, two or three or more 
markers 
0 markers 1 marker 2 markers 3 or more markers 
Healthy 25 5 3 0 
Patients 15 18 19 16 
Figure 6.8. A graphical representation of the analysis of the numbers of markers expressed in blood 
samples from CMM patients and healthy volunteers. *denotes a statistically significant difference between 
CMM patients and healthy volunteers. Table shows the number of CMM patients and healthy volunteers 
that expressed zero, one, two or three or more markers. 
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Table 6.6. Statistical analysis of the difference in expression of zero markers in blood samples 
from CMM patients and healthy volunteers (Chi-Square Tests). 
Asymp. Sig. Exact Sig. (2- Exact Sig. 
Value Df (2-sided) sided) (1-sided) 
Pearson Chi-Square 26.784(b) 1 .000 
Continuity Correction( a) 24.586 1 .000 
Likelihood Ratio 27.302 1 .000 
Fisher's Exact Test .000 .000 
Linear-by-Linear Association 26.519 1 .000 
N of Valid Cases 101 
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 13.07. 
Table 6.7. Statistical analysis of the difference in expression of two, and three or more markers in 
the blood of CMM patients and healthy volunteers. 
Statistical analysis of expression of two markers in CMM patients relative to healthy volunteers. 
(Chi-Square Tests) 
Asymp. Sig. Exact Sig. (2- Exact Sig. 
Value Df (2-sided) sided) (1-sided) 
Pearson Chi-Square 5.623(b) 1 .018 
Continuity Correction( a) 4.477 1 .034 
Likelihood Ratio 6.305 1 .012 
Fisher's Exact Test .021 .014 
Linear-by-Linear Association 5.564 1 .018 
N of Valid Cases 95 
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 7.64. 
Statistical analysis of expression of three or more markers in CMM patients relative to healthy 
volunteers. 
(Chi-Square Tests) 
Asymp. Sig. Exact Sig. (2- Exact Sig. 
Value df (2-sidedf sided) (1-sided) 
Pearson Chi-Square 9.226(b) 1 .002 
Continuity Correction( a) 7.546 1 .006 
Likelihood Ratio 14.080 1 .000 
Fisher's Exact Test .001 .001 
Linear-by-Linear Association 9.135 1 .003 
N of Valid Cases 101 
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.23. 
6.1 0. Number of makers expressed in relation to tumour depth 
To facilitate analysis of whether primary tumour depth influences marker 
expression, the number of markers expressed in each of the CMM patient depth 
groups were evaluated separately as shown below in Figure 6.9. Analysis 
shows that while CMM patients with a tumour depth ~2.00mm expressed no 
markers more frequently than those with in situ and >2.00mm tumour depths, 
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these differences were not significant. In contrast, patients with a tumour depth 
>2.00mm were significantly more likely to express three or more markers than 
those with s2.00mm tumour depth (Fisher's exact test: p=0.004,df=1; table 6.8). 
Number of markers expressed in CMM patients relative to 
tumour depth 
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Figure 6.9. Graphical representation of the analysis of the number of markers expressed in the peripheral 
blood of CMM patients with tumours >2.00mm in depth relative to those with tumours :s2.00mm in depth. 
* denotes a significant difference between CMM patients with a tumour depth >2.00mm and those with a 
tumour depth :s2.00mm. Table shows the number of patients in each depth category expressing zero, one, 
two and three or more markers 
Table 6.8. Statistical analysis of the expression of three or markers in the blood of CMM patients 
with a tumour depth >2.00mm in relation to those with a tumour depth s2.00mm (Chi square 
tests). 
Asymp. Sig. Exact Sig. (2- Exact Sig. 
Value df (2-sided) sided) (1 -sided) 
Pearson Chi-Square 9.553(b) 1 .002 
Continuity Correction(a) 7.548 1 .006 
Likelihood Ratio 10.759 1 .001 
Fisher's Exact Test 
.004 .002 
Linear-by-Linear Association 9.354 1 .002 
N of Valid Cases 48 
a Computed only for a 2x2 table 
b 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.50. 
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6.11. Marker expression in relation to time since diagnosis 
In order to assess whether the time since diagnosis of CMM and removal of the 
tumour has an effect on marker expression in patients, gene expression was 
analysed relative to the time since the patient's diagnosis and tumour removal 
(ie. s1 year or >1 year since tumour removal). Figure 6.10 depicts expression of 
each marker in CMM patient blood relative to time since diagnosis. Analysis 
reveals that although marker expression is generally less common in the >1 
year group and PAX3d shows the biggest difference relative to time since 
diagnosis, there is no significant difference in marker expression relative to time 
since diagnosis. Figure 6.11 shows the number of markers present in CMM 
patient blood relative to time since diagnosis. Similarly, analysis shows that 
although three or more markers show the biggest difference relative to time 
since diagnosis, there is no significant difference between the numbers of 
markers expressed in relation to time since diagnosis. 
Expression of markers in relation to time since diagnosis 
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Figure 6.1 0. Graphical representation of the analysis of CMM patient marker expression in relation to time 
since diagnosis. Table shows the number of patients showing expression of each marker relative to time 
since diagnosis. 
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Figure 6.11. Graphical representation of the analysis of the number of markers expressed in CMM patient 
blood in relation to time since diagnosis. Table shows the number of patients expressing zero, one, two or 
three or more marker relative to their time since diagnosis. 
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7. DISCUSSION 
7 .1. Overall marker expression 
Smith and colleagues (199.1) determined that molecular markers specific to 
melanocytes could be used to detect migrating melanoma cells in peripheral 
blood. Following this discovery, many studies have investigated the use of 
these and other markers of melanoma metastasis, including genes responsible 
for the proliferation, invasiveness and survival of melanoma cells in peripheral 
blood assays. Assays to determine this expression included RT-PCR and 
ELISA methodologies. (Carreira et a/., 2005; Lang et a/., 2005; Wagner and 
Fisher, 2005). Since melanomas are highly heterogeneous with respect to 
tumour-related gene expression, multi-marker RT-PCR was developed to 
improve assay sensitivity (Medic et a/., 2007). This procedure uses the 
simultaneous detection of several markers of melanoma cells to allow for the 
variation in expression of genes (Hoon et a/., 2000; Reynolds et a/., 2003). In 
this study, markers of melanocyte development were used together with 
markers of melanoma progression, to determine the efficacy of this combination 
of markers in a multi-marker assay. Markers were assessed in combination and 
individually for efficacy by statistical analysis. 
Of the markers used here, PAX3d, MITF and MART1 have previously been 
identified individually as significant markers of melanoma metastasis in tissue 
and peripheral blood samples (Blake and Ziman, 2003; Koyanagi eta/., 2006; 
Medic, 2006; Wascher eta/., 2003). To date the efficacy of SFRP5 and TGF{32 
have not been investigated as markers of melanoma cells in peripheral blood 
(Jones and Jomary, 2002; Reed et a/., 1994). Although TGF{32 has been 
implicated as a marker of melanoma progression in tissue (Reed et a/., 1994 ), it 
remains to be conclusively tested in both tissue and peripheral blood. 
In this study, the choice of markers and their use in combination proved 
successful; overall, 77.9% of patients examined showed expression of at least 
one marker. This is a considerable improvement on the results of some multi-
marker assays from several other recent studies, which showed 60% (Schmidt 
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eta/., 2006), 55% (Koyanagi eta/., 2005), 51.5% (Samija eta/., 2004) and 47% 
(Reynolds eta/., 2003) ~verall expression of at least one marker. The markers 
selected for multi-marker assay in the current study differed from the markers 
trialed in these previous studies. This increased frequency of marker expression 
suggests that this combination was better suited to the detection of 
heterogeneous melanoma cells. Alternatively, this difference in results may be 
due to the smaller number of patients (68) used in the current study, relative to 
previous studies of 118 (Reynolds eta/., 2003) and 94 (Koyanagi eta/., 2005) 
patients, respectively. The lower sample size increases the significance of 
detection in a single patient. However the study undertaken by Samija and 
colleagues (2004) used a smaller patient cohort, dispelling this reasoning. This 
increase in detection of mRNA markers is more likely to be due to the careful 
optimization of blood collection and RT-PCR protocols performed in this study 
(see section 5: methods). 
Multi marker trials that have resulted in higher frequency of marker detection 
such as 82% (Palmieri et a/., 2003) and 93% (Hoon et a/., 2000) overall 
expression of at least one marker, used very different combinations of markers, 
but similar techniques. Ultimately, a set of markers that optimally detects 
melanoma cells in peripheral blood is likely to include markers used in this and 
other successful studies. 
7.2. Analysis of individual marker suitability for inclusion in a blood test 
for CMM metastasis 
This study showed that MITF and TGF{32 are reliable markers of melanoma 
cells in peripheral blood, in line with previous studies that have described the 
expression of these genes in CMM tissue (M/TF and TGF{32) (Reed eta/., 1994; 
Wascher eta/., 2003) and peripheral blood (MITF) (Koyanagi eta/., 2006). The 
fact that neither . gene was expressed in the blood of healthy volunteers 
strengthens the assumption that their observed expression in peripheral blood 
of CMM patients arises from melanoma cells. 
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MITF expression was detected in 44% of CMM patients, which is notable when 
compared to other recent studies which showed expression of this gene in 39% 
(Koyanagi eta/., 2006) and 30% (Samija eta/., 2004) of patients tested. Since 
the number of patients used here was midway between those used in the 
previous studies, the higher frequency of detection is more likely due to careful 
optimization of methodologies of blood collection and RT-PCR procedures. 
TGF{32 was expressed in 25% of melanoma patients and with no previous 
studies of this type utilizing this gene, no comparisons are possible. However 
relative to other markers in this study expressing 44% (MITF), 48.5% (MART1), 
25% (PAX3d) and 19% ( SFRP5), this can be deemed a considerable 
proportion. Accordingly, both MITF and TGF{32 are considered to be valuable 
markers of migrating melanoma cells, and are suitable for inclusion in a blood 
test for CMM metastasis. 
In this study, MART1 was found to be expressed in the peripheral blood of both 
CMM patients (48.5%) and healthy volunteers (9%). Chi-square analysis of 
these results show that MART1 is significantly more likely (p=O.OOO) to be 
expressed in CMM patients than in healthy volunteers. Therefore the gene is 
considered a valuable marker of melanoma cells in peripheral blood and 
suitable for inclusion in a blood test for CMM metastasis. 
MART1 expression in 48.5% of patients is considerably higher than in previous 
studies which showed 30% (Koyanagi eta/., 2005), 32% (Palmieri eta/., 2003), 
17% (Reynolds et a/., 2003) and 10% (Wascher et a/., 2003) expression in 
CMM patients respectively. Interestingly, Keilholz and colleagues (2004) also 
found expression of MART1 in the blood of healthy volunteers (14.3%). To 
offset the effect of the false positives in healthy volunteer samples, Keilholz and 
colleagues (2004) used quantitative real-time RT -PCR to set a cut-off level of 
expression of the gene to distinguish between healthy and patient samples as 
expression levels. of MART1 were lower in controls. This option was not 
possible in the current study, as the RT-PCR assay used here was not 
quantitative. Future studies will employ Real-Time RT -PCR to further evaluate 
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the efficacy of the markers identified as suitable in this study. This proposition 
will be explained in mor~ detail later. 
In this study, PAX3d and SFRP5 were found to be poor markers of melanoma 
cells in the blood due to the expression of these genes in healthy volunteers. 
When analyzed statistically, expression of both genes was found to be similar in 
CMM patients and healthy volunteers, with no significant difference in 
expression noted between these groups. 
The PAX3d result contrasts significantly with that of Medic (2006) in which 
PAX3d expression was found in 52.4% of CMM patients but not in healthy 
volunteers. PAX3d was therefore considered to be a useful marker of CMM 
metastasis (Medic, 2006). The variation in results may indicate that some of the 
healthy volunteers recruited in the current study may have CMM but be clinically 
undiagnosed. Alternatively, a much smaller number of healthy volunteers was 
used in the previous study and this may explain the lack of expression of the 
marker in healthy volunteers (Medic, 2006). 
This is the first study to date to investigate the use of SFRP5 as a marker of 
melanoma cells in the blood. Results suggest that this is not a suitable marker 
of migrating melanoma cells in peripheral blood of CMM patients. Analysis of 
expression of this and other SFRP g~nes will be tested in tissue sampled prior 
to further blood tests. 
Overall this study found MITF, TGF/32 and MART1 to be useful markers of 
melanoma cells circulating in peripheral blood and suggest that they would be 
suitable for inclusion in a multi marker assay designed to identify migrating 
melanoma cells in peripheral blood of CMM patients. 
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7.3. Analysis of efficacy of individual markers as indicators of disease 
progression 
Breslow (1975) showed a significant correlation between patient tumour depth 
and prognosis. This correlation remains the gold standard in CMM prognostic 
techniques. This study utilized this correlation to investigate marker efficacy, by 
analyzing marker expression relative to primary tumour depth. The only marker 
that shows increased expression with increased tumour depth is TGF{32; that is 
TGF{32 is significantly more likely to be expressed in CMM patients with a 
primary tumour depth greater than 2.00mm than in patients with in-situ 
melanoma or tumours ~2.00mm in depth. The observation that TGF{32 is 
expressed at a higher rate in patients with thicker tumours supports the 
association between this gene and the deep invasion and metastasis of CMM 
(Reed et a/., 1994). Accordingly, this gene may be useful as a prognostic 
marker if included in a blood test for CMM progression. 
Another marker that showed differing expression in relation to primary tumour 
depth was MART1. However, unlike TGF{32 this marker did not align with 
advancing clinical stage of the disease. Rather, patients with in situ melanoma 
or those with >2.00mm tumour depth were significantly more likely to express 
MART1 than patients with a primary tumour depth ~2.00mm. This suggests that 
MART1 may be down-regulated at certain stages of the disease, before being 
up-regulated again during deeper invasion. Alternatively, and a more likely 
explanation, is that these results are inaccurate due to small group numbers. 
7.4. Number of markers relative to disease progression 
Several studies have shown that the number of markers detected in blood 
samples from CMM patients is directly related to the clinical stage of the 
disease, with more advanced tumours showing an increased number of 
markers (Hoon eta/., 2000; Koyanagi eta/., 2005; Wascher et a/., 2003). By 
contrast, this study found that there was no significant correlation between the 
tumour depth and the number of markers. 
60 
This difference in results may be due to the small number of patients utilized 
here, or to the difference in classification of disease progression between 
studies. In the current study, disease progression was attributed to a deeper 
primary tumour according to the Breslow system of tumour grading (Breslow, 
1975), which is still the only system used by pathologists in Western Australia. 
Previous studies have used the more accurate AJCC classification system of 
disease progression (Balch et a/., 2001 ). While Breslow's system of tumour 
grading shows a relationship between tumour depth and patient survival, it does 
not take into account the presence of ulceration or the presence of disease 
spread measured by lymph node involvement and/or distant metastases. 
Alternately, the markers used in this study were not necessarily associated with 
tumour progression. While TGF{32 is thought to be associated with tumour 
progression (Reed et a/., 1994 ), confirmed by frequent expression in patients 
with thicker tumours (this study), its role in tumour metastasis remains to be 
determined. 
It was expected that patients with in situ tumours would express the fewest 
markers of CMM patients. At this early stage of disease, a tumour is not 
considered to be invasive (Pantel et a/., 1999) and therefore not expected to 
have as many tumour cells circulating in the blood stream (Koyanagi et a/., 
2005). Also, at an earlier stage of CMM there is thought to be less genetic 
instability and therefore less likelihood of expression of multiple melanoma 
mRNA markers (Hoon et a/., 2000). In this study, the number of markers 
detected in samples from CMM patients with in situ melanoma was similar to 
the number of markers detected in samples from patients with a >2.00mm 
tumour depth. This suggests that even at this early stage of the disease, there 
is some invasion of melanoma cells into the bloodstream, although their 
metastatic potential has yet to be assessed. This is not necessarily a limitation, 
and may in fact be a positive finding. Firstly, the markers utilized here could be 
used in a blood test for melanoma detection rather than progression. Secondly, 
the finding that patients with early clinical staged tumours express markers of 
migrating melanoma cells in peripheral blood is a novel finding and may lead to 
more careful monitoring of these patients (discussed further later). 
7.5. Number of markers expressed in patients relative to healthy 
volunteers 
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This study shows that CMM patients are significantly more likely to express two 
or more markers than healthy volunteers. This suggests that a blood test 
incorporating these markers would require expression of at least two markers to 
give an accurate result for melanoma markers circulating in peripheral blood. 
In this study, 24.2% of healthy volunteers showed marker expression, of which 
9.1% expressed two markers. Due to its poor result as a marker of melanoma 
cells in the blood, SFRP5 would not be incorporated in future blood tests for 
CMM. Had this marker not been included in this study, fewer than 20% (18.2%) 
of healthy volunteers would show positive marker expression, and none would 
show expression of more than one marker. However, the removal of SFRP5 
from the multi-marker assay does not lead to a change in statistical significance 
of the number of markers expressed in CMM patients relative to healthy 
volunteers; that is, there is no significant difference in the expression of one 
marker between patients and healthy controls, and CMM patients would still be 
significantly more likely to express two or more markers than healthy 
volunteers. 
The expression of markers in the peripheral blood of healthy volunteers may be 
due to contamination during the processes of RNA extraction and purification or 
to the unspecific nature of the markers to CMM. That is, the markers detected in 
healthy volunteers may be expressed in cells other than melanoma cells. As 
described previously, the identification of markers in the blood of healthy 
volunteers may also be caused by melanoma as yet undetected by the 
individual. 
7.6. Marker expression relative to time since diagnosis 
Interestingly, this study showed no significant difference between the individual 
markers, or the number of markers expressed, in relation to the time since 
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patient diagnosis and surgical excision of the tumour. It was expected that fewer 
markers would be detec!ed or fewer patients would express molecular markers 
in their blood of patients when analyzed at a greater length of time since tumour 
removal. It was expected that melanoma cells in the blood would either form 
metastases or expire (Pantel eta/., 1999). 
The ability of tumour cells to evade the immune system is well documented 
(reviewed in Gorter and Merib, 1999), The up-regulation of anti-apoptotic genes 
such as BCL2 is regarded as one of the ways in which these cells avoid 
destruction (Campana et a/., 1993). As described previously, aberrant 
expression of MITF in melanoma may cause over-expression of BCL2 (McGill 
eta/., 2002) generating immortal melanoma cells that may continue to circulate 
in the blood for several years after diagnosis and surgical excision of the 
primary tumour. Furthermore, TGF{32 is known to act as an immunosuppressive 
molecule in several other cancers and is thought to contribute to decreased 
immune surveillance, allowing tumour development, by inhibiting interleukin-1 
stimulated proliferation of T cells (Bodmer et a/., 1989; Ellingsworth et a/., 
1988). 
7.7. Novel findings: marker expression in the blood of in situ melanoma 
patients 
Surprisingly, this study showed that in situ melanoma patients were as likely to 
express markers of melanoma cells in peripheral blood as patients with a 
tumour depth of :::;2.00mm and even >2.00mm. This was unexpected as in situ 
melanomas are considered to be non-invasive and therefore not expected to 
have invasive cells, or cells that invade the reticular dermis and blood (Meier et 
a/., 1998; Miller and Mihm Jr, 2006; Pantel eta/., 1999). 
This is a disturbing discovery as it suggests that there may be some potential 
for melanoma cells to circulate within the blood of in situ melanoma patients, 
formerly thought to be safe from CMM metastasis. Furthermore, as previously 
stated there is no significant difference in the expression of markers in patients 
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with in situ tumours relative to their time since diagnosis. This implies that 
possibly metastatic melanoma cells may be circulating in the blood of in situ 
patients for several years after the surgical removal of their tumour. This is an 
area not previously studied as in situ tumours are not included in studies of 
markers of melanoma cells in peripheral blood. These results suggest that 
patients with these tumours be included in future marker expression studies of 
migrating melanoma cells. 
7.8. limitations of the study 
The principal limitation of this study was sample size. The low number of CMM 
patient samples analyzed affected the results since many of the analyses failed 
to reach statistical significance due to small group sizes, limiting the conclusive 
observations that can be made from the data. 
Time was a second limitation. With only four months in which to process, purify 
and test RNA, as well as performing RT -PCR analysis for six markers ( GAPDH, 
PAX3d, MITF, MART1, SFRP5 and TGF/32) the number of samples that could 
be tested was restricted. 
7 .9. Conclusion 
Following the isolation, purification and quality assurance of total RNA and 
mRNA, CMM patient and healthy control samples were analyzed using RT-PCR 
for the expression of genetic markers PAX3d, MITF, MART1, SFRP5 and 
TGFf32. Overall, the multi-marker assay trialed in this study proved successful 
with 77.9% of blood samples from CMM patients expressing one or more 
markers, while only 24.2% of blood samples from healthy volunteers expressed 
one or more markers. Of the genes tested, MITF, TGF/32 and MART1 were 
found to be reliable markers of melanoma cells circulating in peripheral blood. 
Furthermore, TGFf32 expression was found to correlate with the presence of 
thicker primary tumours from CMM patients. Although no association was found 
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between the number of markers expressed and increased tumour depth, CMM 
patients were found to_ be significantly more likely to express two or more 
markers than healthy volunteers. Surprisingly however, there was no correlation 
between marker expression and time since CMM patient diagnosis and tumour 
removal, a fact that may be attributed to the gene regulation of tumour cell 
survival. 
Based on these results, further investigation is required to assess the levels of 
expression of these markers in peripheral blood relative to tumour progression. 
7.10. Further studies 
In order to further investigate the level of expression of these markers in CMM 
patient and healthy volunteer peripheral blood, it is necessary to utilize 
quantitative Real Time RT-PCR. It is thought that levels of expression are likely 
to be related to primary tumour depth and/or tumour progression as shown in 
previous studies (Hoon et a/., 2000; Koyanagi et a/., 2005; Wascher et a/., 
2003). Preliminary attempts were made during the study to utilize this 
methodology; however limitations hampered the development of this technique. 
In future studies it is also import~nt to clarify that marker expression is 
definitively associated with CMM tumour presence. That is, healthy volunteers 
must be clinically tested by a dermatologist and declared melanoma free prior to 
their inclusion in the study. Furthermore, peripheral blood from patients 
diagnosed with skin cancers other than CMM should be tested with these 
markers to clarify that marker expression is associated with melanoma cells in 
peripheral blood. 
Finally, the inclusion of more samples would allow significant statistical values 
to be obtained for all study groups. A higher number of samples would ideally 
incorporate patients with differing clinical stages of CMM as well as different 
times since diagnosis and tumour removal. 
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Appendix A 
EDITH COWAN UNIVERSITY MEMO 
FACULTY OF COMPUTING, HEALTH AND SCIENCE 
Human Ethics Subcommittee 
TO: 
FROM: 
SUBJECT: 
DATE: 
Tamara Harold, Admin. Officer, Higher Degrees 
Angus Stewart, Chair, Faculty Human Ethics Subcommittee 
Human Ethics Clearance Application/s 
nth July, 2007 
Dear Tammie, 
The following ethics application 
Development of a blood test for the 
detection of Cutaneous Malignant 
Rebecca Slattery Melanoma. 
is approved (category 1). 
Best wishes, 
Angus. 
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Appendix B 
RNA (GENE EXPRESSION) TESTING 
The purpose of this document is to provide information 
relating to 
procedures for RNA (Gene Expression) testing 
This document explains the ethical issues and provides 
a code of practice for gene testing as laid down by the 
National Health and Medical Research Committee of 
Australia, and is provided in addition to the specific 
project information sheet. 
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WHAT IS RNA? 
Your genes are composed of a chemical molecule called DNA. RNA, a similar 
chemical compound, is copied from DNA by enzymes in each cell of your body. 
RNA provides the blueprint for the synthesis of proteins. These compounds are 
often referred to as the BUILDING BLOCKS OF LIFE. 
Each RNA molecule is expressed from a specific gene present on DNA. RNA 
provides the code and signal for manufacture of proteins. Therefore once the 
specific signal RNA is received in the cell the corresponding protein is made. 
Each gene in your DNA is only expressed when needed by the cell; in fact the 
expression of most genes into RNA is carefully controlled occurring only at 
specific times and in specific cells. Many genes are specifically expressed 
during embryonic development and their expression specifies the carefully 
controlled specification, migration, proliferation and differentiation of particular 
types of cells required for the development of organs and tissues. Aberrant 
unregulated expression of these genes into RNA and then into protein in adult 
cells could result in abnormal proliferation and/or migration of these adult cells 
and formation of a tumour. 
RNA testing can provide information on what may be happening in your cells 
right now (specific RNA testing) or what may happen to your general health, or 
perhaps that of your family, either now or in the future (general RNA testing). 
In this project, an RNA test is performed to assist the researchers to assess 
abnormal gene expression as a marker of cells in peripheral blood of patients 
which will assist with identification of abnormal gene expression in the process 
of skin cancer. 
WHY IS RNA TESTED? 
RNA testing can assist us to understand how your cells function or it can assist 
us to understand a disease (specific test), or it can be used for general medical 
research (general test). Medical research helps us find out about our cells and 
tissues and diseases and what causes them. This document gives you 
inform'ation about providing samples for research for a set of RNA tests to be 
used in this research. 
INFORMED CONSENT 
RNA testing is carried out with your full consent. 
Should you agree to RNA testing for research purposes, you are given an 
information sheet and consent form to read and sign. 
We recommend that you give careful consideration to the important 
supplementary information set out in this document before providing your 
consent. 
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HOW IS RNA OBTAINED? 
RNA is usually obtained from a sample of tissue or blood. The amount of tissue 
required may vary but usually, 2mm is required. For blood, only 5ml of blood is 
required and from the blood, RNA is obtained by chemical separation and 
column centrifugation to remove blood cells. For this study, only a small sample 
of blood is taken as this is sufficient for the RNA tests that we are to perform. 
For this study you will be required to provide samples of blood once as a control 
or more than once as a patient (to a maximum of four times per person - please 
see schedule on consent form). 
Isolation of the RNA results in the destruction of the cancer cells. The extracted 
RNA appears as a clear fluid (like water) and is kept in a small plastic tube. The 
sample is stored in a freezer until the end of the research. The sample will be 
labelled with an identification number given by your doctor and by the principal 
researcher. The number is not in any way connected to you and does not 
include your personal identification details. Only routine clinical data in your 
medical records may be given to the researcher, such as your age and sex as 
well as your clinical diagnosis. 
RNA is long lasting and may be stored for an indefinite period of time and 
for the purposes of this research your RNA will be stored while the 
researchers conduct their research and then it will be discarded at the end 
of the research. 
-That is, the sample is to be discarded after it has been used for 
melanoma research only and will not be used for any general RNA testing 
at a later stage. 
You will be required to acknowledge on your Consent Form that you are 
prepared to donate your RNA sample on the understanding that you will not 
receive, or be entitled to, any financial reward or remuneration for providing this 
sample. 
The value of the research is not known at this time. You will be notified of the 
results of the RNA research in general terms at your request- i.e. your specific 
details are not recorded but the outcomes of the research as a whole is 
provided to you upon completion of the project. 
TISSUE SAMPLE HANDLING 
If you decide to provide your tissue sample for research purposes, you can be 
assured that in this case, your sample is only used for melanoma research and 
there is no possibility that future RNA testing may result in new information 
about other diseases that you may carry. 
THE CHIEF INVESTIGATOR'S COMMITMENT TO YOU 
RNA testing is a. complex and changing area. The Chief Investigator will 
endeavour to protect your interest at all times. Your RNA sample is treated 
exactly as indicated above and is monitored by the Chief Investigator at all 
times and is dealt with as indicated in the signed consent form. 
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Your sample is stored carefully, but a guarantee cannot be given against 
inadvertent loss or damage which is beyond the Chief Investigator's control. 
We guarantee that your sample is NOT to be used for other tests, and is 
discarded upon completion of the research. 
All research to be conducted has the approval of Edith Cowan University 
Human Research Ethics Committee and the Human Research Ethics 
Committee at Sir Charles Gairdner Hospital. 
All experiments are conducted under the strict guidelines of the Australian 
National Health and Medical Research Council. 
Should you advise your family members? 
1. You may advise your family members of the existence of your RNA 
sample; perhaps even provide them with a copy of this Information 
Brochure and your signed Consent Form. 
2. Advise your family members of the purpose for which you have provided 
your RNA sample and bring them with when you donate your sample if 
you wish. 
3. However in this project we are not testing for association with genetically 
determined diseases. The information will not be used to alter your 
treatment in any way. It may however at some future stage provide 
information about the relationship between gene expression and tumour 
progression. Your sample will assist with this research but we cannot 
provide conclusive details about this until the conclusion of the research. 
We are not specifically testing your future health or that of your family in 
this research project. 
WHAT IF I CHANGE MY MIND? 
You maintain the right to withdraw your consent and sample at any time. 
If you wish to have your sample withdrawn, notify the Chief Investigator in 
writing. It will then be discarded in an .appropriate and timely manner. 
DO YOU HAVE FURTHER QUESTIONS? 
If you have any questions about RNA testing, please contact your doctor or the 
Chief Investigator of the research study. 
Any concerns you may have regarding the manner in which the research project 
is conducted, may be directed to:-
Kim Gifkins 
Research Ethics Officer 
Edith Cowan University 
100 Joondalup Drive 
JOONDALUP WA 6027 
Phone: (08) 6304 2170 
Fax: (08) 6304 2661 
Email: research.ethics@ecu.edu.au 
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JOONDALUP CAMPUS 
100 Joondalup Drive, Joondalup Western Australia 6027 Telephone (08) 6304 5555 
Postgraduate Coordinator 
Sports Science 
and Science 
EDITH COW AN UNIVERSITY 
PERTH WESTERN AUSTRALIA 
I 00 Joondalup Drive, Joondalup 
Western Australia 6027 
Telephone +61 8 9400 5555 
Facsimile +61 893001257 
ABN 54 361 485 361 
Dr. Mel Ziman 
Senior Lecturer and 
School of Biomedical and 
Faculty Communications, Health 
Edith Cowan University 
1 00 Joondalup Drive 
Western Australia, 6027 
Ph: 6304-5171 
Fax: 6304-5717 
Email: m.ziman@ecu.edu.au 
Consent for Blood to be utilized for Gene Expression 
Testing Research 
I, ................................................... of ...................................... .. 
have read the Information Document entitled "RNA (Gene expression) 
Testing" and the Information Sheet for the study. 
I hereby consent to a blood sample being taken and donate the sample for 
research as indicated in the information document. 
As my sample is a control sample and I have not been diagnosed with 
skin cancer and I do not wish my personal details to be recorded then 
I have every right not to provide these details. This means that the 
researchers cannot contact me at a future date and the risks and 
benefits of this have been explained to me in detail. 
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If the research produces· information relevant to my health and wellbeing, this 
information will be provided to me (if I wish to be notified) and my clinician will 
be consulted to allow me to obtain appropriate medical attention should this be 
necessary. 
It is important for you to understand that the information gathered from your 
sample forms part of a research project. If any abnormal result is obtained from 
your sample then this needs to be verified by clinical testing. 
If you do not provide contact details now so that we can contact you at a later 
date then this information is not available to you and your samples will be 
completely de-identified unless you specifically request that you remain 
contactable, in which case details that allow us to contact you, are required. 
Your sample will then be provided with a code for use by the researchers and 
all personal information will be held in locked filing cabinets. 
In making my donation of blood, I understand and agree that: 
(a) the sample (which in this consent form includes its constituents and 
any genetic material (RNA) will be used only in relation to 
melanoma research; and 
• will be stored in a tissue bank for the duration of the melanoma 
research conducted by researchers at Edith Cowan University. 
(b) Taking and storage of samples will be conducted in accordance with 
the National Health & Medical Research Council's* Guidelines for 
Genetic Material. 
(c) Storage of RNA will be conducted under a coded system, to ensure 
that donor confidentiality is maintained; 
(d) samples of RNA will be discarded upon completion of the research 
·· or upon my written request; 
(e) the results of these studies may be of interest to me and my family 
and I may decide whether or not the information may be disclosed 
to my family; in accordance with Options for disclosure to family 
members. However, the research will not at this stage provide me 
with any detailed information about any genetic diseases. However 
donation of my sample may assist researchers to provide a more 
detailed and specific diagnosis of melanoma in the future. 
*The National Health & Medical Research Council advises the Australian 
community and Commonwealth and the State Governments on standards 
of individual and public health, and supports research to improve these 
standards as follows: 
(f) if a research worker wishes to obtain additional information or 
samples from me, my name will not be divulged to that researcher 
without my written permission; 
(g) the fact that I have had a test, and the results of my test, will not be 
revealed or made available to any other person or organisation except in 
accordance with my written consent, 
(h) the Chief Investigator of this project and his or her associates involved 
with this project as well as Edith Cowan University will not be liable for any 
loss or damage to the sample taken or used in accordance with this form. 
• I consent to the storage of my RNA for melanoma research as 
explained in the related Information Sheet 
I acknowledge the public interest in the research and donate the 
sample absolutely on the understanding that I will not receive, or be 
entitled to, any reward or remuneration for providing my RNA. 
I understand the potential benefits and adverse consequences (if any) 
involved in testing of this sample. These have been explained to me and 
I accept the risks involved. I have had the opportunity to ask questions 
and am satisfied with the explanation and the answers to my questions. 
I understand that I may withdraw my consent at any stage without 
reason and without prejudice. 
Name of Participant Signature Date 
Name of Witness Signature Date 
Name of Chief Investigator Signature Date 
The Human Research Ethics Committee at Edith Cowan University requires that all 
participants are informed that, if they have any complaint regarding the manner in 
which a research project is conducted, it may be given to the researcher or, 
alternatively, to 
Kim Gifkins 
Research Ethics Officer 
Edith Cowan University. 
100 Joondalup Drive 
JOONDALUP WA 6027 
Phone: (08) 6304 2170 
Fax: (08) 6304 26(31 
Email: research.ethics@ecu.edu.au 
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